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ABSTRACT
Aim: To examine the long term outcomes of hepatitis C virus (HCV) infection in a cohort of 
patients admitted with acute viral hepatitis between 1971 and 1975. The availability of stored sera 
enabled testing to identify anti-HCV positive subjects.
Methods: A retrospective cohort study design was chosen. The exposure of interest was the 
presence of anti-HCV in stored sera. Systematic approaches were used to locate the cohort and 
outcomes assessed with the SF-36 questionnaire, a study specific questionnaire and by clinical, 
serological, virological and biochemical assessment.
Results: Sixteen percent (n=238) of the cohort tested anti-HCV positive and formed the exposed 
group. The unexposed group (n=476) was randomly selected from those who were anti-HCV 
negative. Complete follow up was achieved on 98 anti- HCV positive individuals and 202 negatives. 
At 25 years follow-up, 54% of the anti-HCV positive group had evidence of chronic HCV infection 
(both anti-HCV and HCV RNA positive). Of those chronically infected 69% had elevated serum 
ALT levels, but only 8% had progressed to overt cirrhosis and no cases of HCC were identified. 
Anti-HCV positive subjects were 4 times more likely to have died from suicide or drug overdose than 
from HCV related disease. Quality of life measures were significandy reduced in the exposed group 
and significandy worse for anti-HCV positive individuals aware of their serostatus, compared to 
those unaware.
Discussion: The reduced quality of life in those aware of their HCV diagnosis may be partially an 
effect of 'labelling’. Anti-HCV positive study subjects were at increased risk of liver related 
pathology after 25 years follow up, but few had progressed to overt cirrhotic liver disease. Excess 
mortality in the anti-HCV positive group wras not due to liver disease. This suggests that the natural 
history of community acquired HCV may be more benign than previously thought.
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CHAPTER 1: INTRODUCTION
1.1
The natural history of Hepatitis C Virus (HCV) remains unclear. Review of available literature 
demonstrates that most data published are either based on studies reporting on transfusion 
acquired cases or cross-sectional studies, mainly from tertiary referral liver centres with their 
inevitable referral and selection bias in estimating proportions and rates of disease progression. 
This data is currently used to project HCV disease burden on a population and individual basis 
despite the fact that in most industrialised nations the principal ongoing route of infection with 
HCV is community acquired, principally through injecting drug use (IDU).
There is a pressing need to establish the natural history of community acquired - as opposed to 
transfusion acquired - HCV infection, and to provide reasonable estimates of disease 
progression as well as long term morbidity and mortality associated with chronic community 
acquired HCV infection. However there are methodological difficulties associated with 
conducting these studies. Firstly, detection of newly acquired infection is problematic as a small 
number of cases appear to display clinical illness and it is not yet possible to identify acute 
HCV by an IgM antibody response. A further issue impeding natural history studies has been 
the difficulty in gaining access to and following for long periods groups at high risk of 
infection, such as injecting drug users (IDUs). In addition chronic HCV runs a protracted and 
highly variable course before the development of adverse outcomes and it may be that four or 
five decades of follow up are required to ascertain fully the impact of HCV infection.
The estimated risk of progression to serious sequelae of HCV infection differs depending upon 
the populations studied, the methods used and the period of follow up. Transfusion related 
studies report rates of progression to cirrhosis of over 20% at 20 years. Liver clinic studies
17
estimate similar or higher rates of progression to cirrhosis, although it is likely that such series 
suffer from considerable referral bias. Studies in anti-D recipients indicate that in certain 
populations the progression of HCV to cirrhosis may be significantly less than the estimates 
from transfusion associated non-A, non-B hepatitis (TA-NANBH) or liver clinic studies.
There have been very few population-based studies in IDUs and none with follow up of any 
significant length. Natural history estimates from such studies are essential as they represent 
more closely current HCV infected populations.
Our planned study was able to overcome many of the problems traditionally associated with 
HCV natural history studies. The population involved has community acquired disease - 
predominantly through IDU, the length of follow up will be sufficient for many of the long­
term consequences of HCV to arise and the duration of disease is documented clearly through 
testing of stored sera from the early 1970s.
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1.2 Aim and Objectives
Aim
The aim of this study is to clarify the burden of disease, disability and death associated with 
community acquired HCV 25 years after initial infection.
Our hypothesis was that the natural history of community acquired HCV is more benign than 
that associated with other modes of transmission, principally transfusion acquired infection. 
We estimated that the rate of progression to cirrhotic liver disease in subjects with community 
acquired infection, would be at least half that observed in those infected through transfusion of 
contaminated blood products.
Objectives
Study objectives were to:
1. Test stored sera from 1971 to 1975 at FIDH for serological hepatitis markers.
2. Identify exposed (anti-HCV positive) subjects and unexposed (anti-HCV negative) cohort 
subjects.
3. Obtain contact information recorded in the original FIDH medical record and 
systematically apply tracing methods to trace and recruit cohort members to the study 25 
years after exposure to HCV.
19
4. Assess the health status of study members with regard to mid and long term sequelae of 
chronic HCV.
5. Document progression to adverse outcomes - including death, liver related morbidity 
(chronic hepatitis, cirrhosis and hepatocellular carcinoma [HCC]) and reduced quality of 
life (QOL).
6. Explore associations with adverse outcomes - virus related, host related and other.
7. Measure QOL in study subjects and explore the impact of knowledge of HCV serostatus 
on QOL.
20
CHAPTER 2: LITERATURE REVIEW
2.1 Genetic Variation of Hepatitis C Virus
HCV is a single-stranded ribonucleic acid (RNA) virus, which is a member of the flaviviridae 
family. Viral replication occurs through an RNA dependent polymerase which results in the 
rapid development of diverse, but related quasispecies within an infected person and presents a 
major challenge to immune-mediated control of HCV.1
HCV isolates demonstrate considerable global genetic variation with the genomic sequences of 
the most distantly related isolates varying by as much as 35%. It is generally accepted that, 
based on differences of its non-structural and core proteins, HCV has evolved into six major 
genotypes with a further 50 subdivisions or subtypes.2
Genotypes are identifiable within particular geographic distributions, with the distribution of 
HCV genotypes in Australia similar to Europe and North America.3 Isolates of genotype 1, 2 
and 3 are widely distributed, but significant variation is seen in the subtypes. Within genotype 1, 
subtype la  is common in western Europe and North America whereas subtype lb  is more 
common in Japan and southern Europe. Genotype 3a is seen commonly in younger western 
populations, especially IDUs, whereas subtypes 3c-3f are found in Nepal and 3b in Japan, 
Thailand and Indonesia. Genotype 4 is found in Africa, except for South Africa, where 
genotype 5 predominates and genotype 6 is seen in Asia.4 5 2 In Australia, genotypes la  and 3a 
are the most frequent isolates.6 Genotypes 4 to 6 are uncommon in Australia, and are mainly 
represented by immigrant groups from areas where such genotypes predominate.7
Genotypes also vary by mode of acquisition, with those contracting HCV via transfusion more 
likely to be infected with subtype lb , whereas those infected via IDU tend to be infected with
21
3a. There is a trend therefore that younger people are more likely to be infected with subtype 
3a, and older people with subtype lb .482
Table 2.1 Distribution of HCV genotypes in Australia 6
Genotype %
1
la 23
lb 16
Undefined 16
2
2a 3
2b 1
Undefined 3
3
3a 38
3b <1
4
4a <1
Undefined <1
The influence of genotype on outcome of treatment with interferon is well established,9 10 
although its influence on transmission or natural history remains controversial.
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2.2 Diagnostic Tests for Hepatitis C Virus Infection
Diagnostic tests for HCV are divided into serological assays for antibodies and molecular tests 
for viral particles.
2.2.1 Antibody Tests
Following the development of HCV antibody (anti-HCV) assays in 1991,11 there have been 
three generations of modifications made to improve the sensitivity and specificity of these 
assays. HCV assays are based on recombinant or synthetic antigens, but the first generation 
assays only contained recombinant antigens from the NS4 region of the HCV genome. The 
sensitivity of these early generation assays was significantly lower for individuals with genotypes 
2b and 3a than for those with genotypes la  or lb .12 The second generation assays reduced the 
number of false-reactive results by incorporating recombinant antigens derived from the core, 
NS3 and NS4 regions.13 14 The addition of such antigens also increased the sensitivity of the 
assays, as antibodies to NS3 are generally the first to appear during seroconversion.14 Third 
generation assays have included NS5 antigens, with some improvement in sensitivity and 
specificity.15 16 Some individuals demonstrate false-reactivity to NS5 which can decrease the 
specificity of certain assays.17
False-negative results occur in infected individuals who may be in the ‘window period’ prior to 
seroconversion and have also been documented in subjects with Human Immunodeficiency 
Virus (HIV) infection.18 False-positive reactions have been recorded in subjects with syphilis, 
rheumatoid arthritis and systemic lupus erythematosis.1921
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2.2.2 Direct Measurement of Viral RNA
The only method to direcdy measure HCV infection is by the detection of viral RNA, typically 
by reverse transcriptase polymerase chain reaction (PCR), although other methods include in 
situ hybridisation and branched deoxyribonucleic acid (DNA) amplification assays. The DNA 
amplification assay is easy to perform and reproducible, but is significantly less sensitive than 
PCR assays.22
Assays can be qualitative or quantitative. Qualitative tests are based on PCR and have a lower 
limit of detection of 100 copies of RNA per ml.23 Genotype and viral load results are used to 
predict the outcome of interferon or combination therapy.910 PCR tests also aid identification 
of infection in individuals who are in the acute stage of infection, but with no detectable 
antibodies.24
The absence of PCR detectable viraemia appears to indicate an extremely low risk of HCV 
transmission by any route. A systematic review by Dore et aP5 identified 29 published studies of 
HCV transmission. They found that in 1148 subjects exposed to anti-HCV and PCR positive 
sources, 148 cases of transmission occurred, compared with no definite case of transmission 
among 874 subjects exposed to anti-HCV positive, but PCR negative sources.
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2.3 Routes of Transmission and Risk Factors for Hepatitis C Virus Infection
2.3.1 Overview
The primary route of transmission of HCV is through percutaneous exposures to blood and 
blood products. The most common exposures associated with transmission are transfusion of 
contaminated blood products and IDU. The relative importance of these two routes of 
transmission has changed over the past two decades. Blood transfusion, which accounted for a 
substantial proportion of HCV infections acquired over 15 years ago, accounts rarely for 
recently acquired infections due to widespread screening of blood donors and products. The 
prevalence of IDU increased dramatically from the early 1980s and is currently the most 
common route of transmission of HCV, due principally to the high prevalence of HCV in IDU 
communities and unsafe injecting practices.
There is a small risk that HCV can be transmitted through sexual contact and also through 
non-sexual household contact. HCV infection can also occur through vertical transmission, as 
well as via therapeutic injections, acupuncture, tattooing, and body piercing if poor infection 
control practices exist.
2.3.2 Injecting Drug Use
Injecting drug users are at risk of a number of infectious diseases, mainly due to the unsterile 
injecting techniques employed as a consequence of the illegal nature of this activity in most 
populations.
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The prevalence of HCV in IDUs in consistently very high across a wide range of populations 
studied (Table 27).26-37
Table 2.2 Prevalence of anti-HCV in injecting drug users
Country Year Sample size Study setting Anti-HCV positive (%)
India 37 1996 191 Community 98%
China 34 1994 507 Drug rehabilitation 95%
Australia 32 1995 1428 Prison entry 64%
New Zealand 31 1995 116 Treatment centre 84%
Italy 33 1994 255 Treatment centres 81%
UK, North England 30 1998 773 Treatment centre 67%
USA, Baltimore 38 1996 312 Community 77%
USA, San Francisco 26 1999 308 Young IDUs 45%
Brazil 28 1999 102 Prison 56%
In other populations, such as sexually transmissible disease (STD) clinic attenders, who are at 
risk of both blood-borne viruses and STDs, a concomitant history of IDU is a strong risk 
factor for infection with HCV.39 Similarly in blood donors found to be anti-HCV positive, 
IDU is again the commonest association.40-42
The strongest association with HCV seroprevalence in IDUs is duration of injecting, and by 
association, age.30 35 36 43*51 3752 However, in certain situations new injectors are at very high risk 
of infection.38 45 53 In one study in the USA, injectors who had been injecting for between five 
to 8 months had an anti-HCV prevalence of 75%.38 Associations with HCV seroprevalence in 
these new injectors were; injecting daily, reusing syringes at least once in the past 6 months, 
injecting the first time with someone > or =5 years older and injecting cocaine or speedball 
exclusively.
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HCV seroposirivity is also associated with increased frequency of injecting.52 43 38 Injecting daily 
has a strong association with HCV, particularly in new or young IDUs.3845 In populations of 
IDUs with low frequencies of injecting the prevalence of HCV is relatively low. 54
Several studies have found associations with HCV seroposirivity and the injection of certain 
drugs. 37 52 55 56 45 51 57 HCV is more common in those injecting heroin or other opiates than 
amphetamines, and where cocaine is commonly injected, there is a very strong association with 
HCV seroposirivity. The explanation for these findings is likely to be the frequency (and 
cumulative frequency) with which the drugs are injected - cocaine users often inject multiples 
times per day - or the risk behaviours of certain injecting networks, rather than any 
characteristics of a particular drug.
The sharing of needles and syringes has also been associated with HCV seroposirivity.37 55 39 31 
43 45 However, there is also evidence of HCV exposure in IDUs who do not admit to a history 
of sharing. A study of young IDUs in a treatment setting in Sydney reported a HCV incidence 
of 11.9% per year among those who reported never sharing needles and syringes, compared to 
30% per year among those who shared.58 A cohort study of IDUs in the Australian State of 
Victoria reported an incidence of HCV seroconversion of 16.3 cases per 100 person years (PY) 
among those who shared, compared to an incidence of 4.3 per 100 PY in those who denied 
sharing.59 This raises the concern that HCV can be transmitted amongst IDUs through other 
injecting behaviours or environmental contamination, not just though the re-use of 
contaminated needles and syringes. Consequentially the control of HCV becomes more 
difficult in IDUs. This may partly explain why the prevalence of Human Immunodeficiency 
Virus (HIV) has remained low in some communities of IDUs who have access to needle 
exchange programmes, while HCV has spread rapidly.27
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Hepatitis C has higher average transmission efficiency than HIV. The rate of HCV virus 
antibody seroconversion among health care workers exposed to needlestick injuries ranges 
from 1.8 to 9%,60 110 compared to seroconversion for HIV after needlestick of 0.3%.61 It may 
be that HCV can be transmitted between injecting drug users on pieces of injecting equipment 
other than needles and syringes i.e. swabs, spoons, water or tourniquets. One study in 
Melbourne studied injecting equipment from 10 different injecting settings for the presence of 
HCV RNA by PCR and found evidence of HCV RNA on 70% of spoons tested, 67% of 
swabs and 33% of spoons implying that HCV could be transmitted through this equipment to 
IDUs who do not share needles.62
2.3.3 Contaminated Blood Products
2.3.3.1 Blood Transfusion Recipients
After the development of serological tests for Hepatitis B Virus (HBV) and Hepatitis A Vims 
(HAV) in the late 1960s and early 1970s, it became apparent that the majority of cases of post 
transfusion hepatitis were associated with neither.63 The term non-A non-B hepatitis 
(NANBH) was developed to describe this type of hepatitis and studies in the mid 1970s 
reported an incidence of about 20% NANBH post transfusion.64 Screening for surrogate 
markers of NANBH (elevated alanine aminotransferase [ALT] and Hepatitis B Core Antibody 
[HBcAb]) from the mid 1980s reduced the risk of transfusion associated (TA) NANBH by 
42%.65
The causative agent for post transfusion NANBH was identified after isolation of the HCV 
vims in 1989 and the subsequent development of an antibody test. Screening using first
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generation assays further reduced post-transfusion HCV risk by 85%, and using second- 
generation assays by 95%.65 66
Currently, HCV is rarely transmitted by blood transfusion. In addition to screening tests and 
the availability of commercial PCR kits, the use of donor interviewing for risk factors and 
donor deferral has led to a reduction in the risk of acquiring HCV infection from blood 
transfusion in Australia to 4.27 per million donations, compared with 0.79 per million 
donations for HIV.67 This data is comparable to figures observed in other industrialised 
countries. 67
2.3.3.2 People with Haemophilia
Receipt of clotting factor concentrates prepared from plasma posed a high risk for HCV 
infection until effective procedures to inactivate viruses, including HCV, were introduced 
during 1985-7. Persons with haemophilia who were exposed to non-heat treated clotting factor 
concentrates before this time have prevalence rates of HCV infection as high as 96%.68 69 
Treatment of blood products from the mid 1980s, and the implementation of HCV screening 
in 1992, essentially eliminated the risk of contracting HCV through heat-treated blood products 
although sporadic cases do still occur.7071 72 Those who are placed on recombinant clotting 
factors have no risk of contracting any blood-borne infections. However, this treatment is 
predominantly given to children and many adults still receive heat-treated blood products.73
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2.3.3.3 Intravenous Anti-D Immunoglobulin.
Human immunoglobulin G (IgG) preparations are used for a variety of clinical indications. 
They are usually administered either by the intramuscular route (IM) or by the intravenous 
route (TV).
Anti-D is manufactured from donations that have high titres of specific antibodies against the 
Rhesus D antigen and used for the prevention of haemolytic disease of the newborn. Almost 
all anti-D is manufactured as IM preparations, rather than as IV preparations.
Two known episodes of transmission of HCV by contaminated anti-D occurred in East 
Germany in 1978 and in Ireland in 1977.7475 Both were associated with IV preparations that 
had been prepared using a procedure that did not include cold ethanol fractionation, which 
contributes towards the removal and inactivation of viruses. This manufacturing process was 
used only in Ireland, Germany and Canada.76
2.3.4 Sexual Transmission
Inconsistencies exist among studies in this area, but current evidence suggests that sexual 
practices are not an efficient means of spreading HCV, in comparison to that of HIV and
HBV.77-96
Wyld et a/.96 reported that over an eleven year study period, 40% of heterosexual partners of 
HCV/HIV co-infected index cases contracted HIV, whereas no one was infected with HCV 
when sexual contact was the only risk factor. However, when heterosexual contact and IDU 
were both present, 52% of partners contracted HIV, and 80% HCV.
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Thomas et aPl evaluated potential transmission of HCV between STD clinic patients, who 
denied other risk factors, and their steady partners. Prevalence of HCV infection among male 
patients with an anti-HCV-positive female partner (7%) was no different than that among 
males with a negative female partner (8%). However, female patients with an anti-HCV- 
positive partner were three times more likely to have HCV infection than females with a 
negative male partner (10% versus 3%,) indicating that similar to other STDs, sexual 
transmission of HCV from males to females might be more efficient than from females to 
males. There is generally no significant difference in HCV transmission with different types of 
sexual behaviour 78
Risk factors found to be associated with HCV in heterosexual populations include greater 
number of partners, not using a condom, history of other STDs and having high-risk partners. 
In homosexual men the risk factors include a history of syphilis, rectal gonorrhoea, anal 
insertive intercourse with ejaculation, and douche or enema use before anal receptive 
intercourse.87
Long-term sexual partners of haemophiliacs or recipients of HCV-contaminated 
immunoglobulin preparations rarely become infected.77 79 85 These discrepancies are not fully 
understood. Other sexual behaviours or confounding non-sexual transmission routes could 
play a part. In addition, the stage at infection (and the resultant level of viraemia) may impact 
on the ability to transmit HCV sexually.
2.3.5 Other Routes
Nosocomial transmission of HCV is possible where poor infection control practices exist. 
Among hemodialysis patients, anti-HCV prevalence averages 30%, but there are significant
31
variations by geographic region; from 0% in a centre in Chile,97 to 28% in an Italian centre,98 
76% in Indonesia,99 and 74-100% in Eastern European centres.100 In the USA, an overall HCV 
prevalence of about 10% was reported in a 1995 survey of 2,647 dialysis centres,101 and similar 
figures have been reported from the UK.102
It is likely that factors other than dialysis alom are responsible for a proportion of HCV 
exposures in these patients. A number of studies have demonstrated an association between 
anti-HCV status and the total number of transfusions and duration of dialysis.103 105 It may be 
that in older subjects much of the HCV exposure is secondary to transfusion of contaminated 
blood products, although HCV prevalence is higher in non-transfused dialysis patients than the 
general population suggesting that nosocomial transmission may also occur. Several reports 
provide evidence of patient-to-patient HCV transmission with environmental blood 
contamination the most significant factor in transmission. There is no evidence that HCV has 
been transmitted by re-use of dialysis machines, but being dialysed next to an HCV positive 
patient is associated with a significant risk of HCV acquisition.106
Unsafe therapeutic injections are associated with transmission of HCV and other blood borne 
pathogens in settings with inadequate infection control practices and can represent a significant 
source of infection. 107-109
Transmission of HCV from patients to health care staff also occurs, although in industrialised 
countries the risk of transmission is low and is related primarily to needle stick injuries. The risk 
of seroconversion after needlestick is documented at 1.8 to 9%.60 110 Transmission rates of 
HCV from health care staff to patient, or patient to patient are very low.
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Perinatal exposures account for a small proportion of HCV infections and appear to occur 
solely in mothers who are HCV RNA positive at the time of delivery. There appears to be no 
increased risk for vaginal delivery or breast-feeding although data is limited.25
Tattooing is also a recognised risk factor for transmission of H CV ,111 although the efficiency 
with which transmission occurs is unknown. One study tested stored sera obtained from 
tattooists in Victoria in the mid eighties for anti-HCV and HBV markers in 1995.112 No sera 
were HIV positive or Hepatitis B Surface Antigen (HBsAg) positive. Of 35 specimens tested 
for anti-HCV, only two (5.6%) were positive despite markers of HBV in 48.6% of the same 
sera.
Despite frequent needlestick injuries reported by tattooists at the time, the low seroprevalence 
of HCV in this group suggests that HCV may not be transmitted efficiently by intra-dermal 
inoculation using solid-bore tattooing needles.
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2.4 Natural History of Hepatitis C
2.4.1 Acute HCV Infection
Persons with acute HCV infection typically are either asymptomatic or have a mild clinical 
illness. The pattern of acute illness is documented most thoroughly in transfusion associated 
cases where 70-80% of cases are anicteric. In a series of 86 consecutive cases of post 
transfusion hepatitis only 30% were jaundiced with a bilirubin concentration greater than 
25mg/dl. Over two thirds had no discernible symptoms and none had protracted severe 
illness.113 It is more difficult to ascertain the clinical picture of acute HCV in community 
acquired infection as individuals are generally identified only if clinically unwell. In one study in 
community acquired infection 70% of people were icteric, but as the cases were ill and had 
sought treatment this is not representative of the usual clinical path of acute HCV.114 
Extrapolation from transfusion studies indicates that clinically apparent illness occurs in no 
more than 25% of HCV infections.113
In a study of community acquired HCV infection, antibody was detected between one week 
and 32 weeks after the onset of dark urine and more than half the patients (54%) had 
seroconverted by four weeks and a third (34%) developed antibodies within two weeks.115 In 
transfusion acquired infection, the average time period from exposure to symptom onset is 6-7 
weeks and from exposure to seroconversion 8-9 weeks. Anti-HCV can be detected in 80% of 
patients within 15 weeks after exposure.113
The course of acute hepatitis C is variable, although elevations in serum ALT levels, often in a 
fluctuating pattern, are its most characteristic feature. Fulminant hepatic failure following acute 
hepatitis C is rare.116 Prevalence of HCV RNA in cases of fulminant hepatitis of unknown 
cause have been reported as being between 0-12% in the USA and Europe, but significantly
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higher (45-59%) in Asia.117 It may be that differences in patient populations or other risk 
factors account for the differences observed.
It is also possible that HCV acts as a cofactor with other viral agents particularly HBV in acute 
liver failure. One study from Taiwan reports an incidence of fulminant hepatitis in subjects 
with underlying HBV infection and superimposed acute HCV of 23%, compared to 2.9% in 
those with HCV infection alone.118 An association between acute HAV infection and fulminant 
hepatitis in subjects with chronic HCV infection was reported by Vento et al,n9 although these 
findings have not been reproduced elsewhere.
2.4.2 Chronic HCV Infection
2.4.2.1 Long Term Outcomes
The significance of HCV lies in its ability to persist in the host and progress -  often 
asymptomatically - over many decades to severe liver disease including chronic hepatitis, 
cirrhosis and HCC. What is not clear is what proportion of individuals infected will progress 
and over what time scale. It is likely that chronic hepatitis C does not have one typical course, 
but can follow a rapidly progressive, slowly progressive or non-progressive route. The 
determinants of severity are not fully understood and are likely to be multifactorial. Viral, host 
and environmental factors are known to influence the course of disease. It is important to 
identify subjects who are likely to progress to cirrhosis -  as they would require early treatment 
and prolonged intensive follow up — as compared to those likely to follow an indolent course.
A wide range of rates of progression to chronicity following acute infection have been reported 
and there is continuing debate about whether an individual can be a healthy carrier of HCV and
have persistently detectable HCV RNA, but no symptoms or signs of chronic liver disease.120* 
123 At the other end of the spectrum are those with persistent viraemia that corresponds to mild 
hepatitis with some inflammatory or necrotic changes, which can progress over time to 
cirrhosis.
Liver biopsy samples are graded according to Histological Activity Index (HAI) which grades 
inflammation on a cumulative 18 point scale based on piecemeal necrosis, confluent necrosis, 
lobular inflammation and portal inflammation. Fibrosis is classified on the following increasing 
severity scale -  no fibrosis, periportal or portal fibrosis, portal-portal bridging, portal central 
bridging and probable or definite cirrhosis.124 In subjects with chronic HCV the extent of 
fibrosis on biopsy is the most important prognostic factor as it is predictive of progression to 
cirrhosis.125 Once an individual develops cirrhosis the symptoms of end stage liver disease can 
appear including marked fatigue, fluid retention, haemorrhage, jaundice, pruritis and muscle 
wasting. At this stage the only effective treatment option is liver transplantation.
Hepatitis C is also associated with a range of non-hepatic manifestations including arthritis, 
keratoconjunctivitis sicca, cryoglobulinaemia and glomerulonephritis.126127
There is also strong evidence to support an association with chronic HCV infection and HCC. 
The pathogenesis of HCV related HCC is unknown, although virtually all reported subjects 
with HCV related HCC have established cirrhosis or advanced fibrosis, which is known p er  se 
to be a precursor of malignancy.128 It may be that HCV induces malignant transformation 
indirectly by causing necroinflammatory hepatic disease and continued hepatocyte 
regeneration, which eventually leads to tumour formation.
The prevalence of anti-HCV in patients with HCC varies in different countries from 72% in 
Italy,129 to 34% in the USA,130 and 13% in Taiwan.131 In regions where HBV is endemic, a well
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documented risk factor for HCC, anti-HCV is present in a smaller proportion of subjects with 
HCC.
The rates of progression to HCC in cohorts with HCV related cirrhosis in the USA and 
Europe varies from 1-3%/year.132-135 The rate of progression in studies from Japan is greater at 
4-7%,136 137 138 for reasons that are not currendy clear.
It is evident that, many years after initial infection, HCV can progress to chronic hepatitis, 
cirrhosis and HCC. However, the estimated risk of progression to long term outcomes of HCV 
infection differs depending upon the populations studied, the methods used and the period of 
follow up. Accordingly natural history studies can be grouped broadly into four main types; 
post transfusion, liver clinic series, population based and newly diagnosed blood donors.
2.4.2.2 Post Transfusion Longitudinal Studies
Several studies have followed subjects prospectively from the onset time of transfusion 
acquired acute NANBH ("Table 2. J).139143
Koretz et a/140 reported on follow up of subjects 16 years after TA hepatitis in the 1970s and 
found that the probability of developing clinical evidence of cirrhosis in subjects with HCV 
(n=64) was 20% after a mean interval of 16 years.
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Table 2.3 Progression to cirrhosis in subjects with transfusion associated HCV infection
Country Year Sample
size
Mean age 
(years)
Mean duration of 
infection (years)
Cirrhosis
prevalence
USA 140 1993 64 65 16 17%
USA 139 1991 39 62 10 20.5%
USA 142 2001 222 61 25 17%
Italy 143 1992 135 54 8 15.6%
Sweden 144 1993 39 55 13 8%
Di-Besceglie et a lm  reported on 39 subjects with NANHB post cardiac surgery’ with morbidity 
and mortality results for 33 subjects. The mean age at transfusion was 52 years and after a 
mean follow up time of 9.7 years (range 1 to 24), 20% had developed cirrhosis and 12% end 
stage live failure. No cases of HCC were reported and no liver related deaths occurred, 
although one third of subjects died during follow up from other causes (the majority from 
progressive heart disease).
Tremolada et a l u i  reported on 135 Italian patients who developed NANBH after cardiac 
surgery and were followed for a mean of 7.5 years (range 1.1 to 15). Of the 65 subjects who 
underwent liver biopsy at the end of follow up, 21 (32%) of those biopsied had developed 
cirrhosis and one (0.7%) HCC. Advanced age at the time of transfusion was significantly 
associated with progression to cirrhosis.
In Sweden, Mattson e t a/reported on thirty-nine subjects followed prospectively for 13 years 
after TA-NANBH. After 13 years follow-up, 1.6% of the patients had died of end-stage liver 
disease, 8% had cirrhosis and three quarters remained chronically infected with HCV.144
The American National Heart, Lung and Blood Institute (NHLBI) study of TA-NANBH 
began in 1987 and followed subjects from five major studies of TA hepatitis in the early 1970s,
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to compare outcomes in 222 subjects who developed TA-NANBH (attributable to HCV) to 
matched transfused subjects from the same studies who had not developed hepatitis. The study 
reported outcomes at 18 years and 25 years.
At 18 years follow-up, all-cause mortality was 51% for those with HCV, compared with 52% 
for controls. Mortality related to liver disease in the cases was 3% and 2% in the controls. 
Thirty percent of those with NANBH/HCV had evidence of chronic hepatitis compared to 
1% of the control group, and of those biopsed, two thirds had evidence of chronic active 
hepatitis (CAH) or cirrhosis.141
At 25 years follow up, the all-cause mortality was high in both groups, but no different between 
cases and controls (67% vs 65%). Liver-related mortality was low (<3%), but significandy 
higher among the cases than the controls. Among HCV infected patients, 23% had 
spontaneously lost HCV RNA and the estimate for progression to cirrhosis was 17%.142
The advantages of such longitudinal studies is that they began at disease onset and have 
reasonable follow up periods (25 years in the NHLBI study).142 In addition, as they include a 
range of subjects - not just those presenting clinically with liver disease - they include those 
with milder disease which gives a more complete picture of the spectrum of HCV related 
disease than studies from tertiary liver centres which only includes those who present with 
established liver disease. However, due to the advanced age of subjects at the time of HCV 
infection, and because so many deaths are attributable to non HCV related disease, they are not 
helpful in determining the outcome of chronic HCV in younger populations or for determining 
the likely outcome of HCV in the third and fourth decades following infection. In addition, as 
the majority of those currendy infected with HCV are IDUs, and because the natural history of 
HCV may differ by route of acquisition - due to the variation in the initial infecting dose - the 
natural history in transfusion recipients may be becoming less relevant.
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2A.2.3 Cross Sectional Studies from Liver Clinics
There have been a number of studies from liver clinics that have estimated progression of liver 
disease at rates similar or higher to those from longitudinal studies of TA-NANBH ( Table 2.4):4
120 128 132 134 136 137 145-165
Table 2.4 Progression to cirrhosis in HCV infected subjects referred to liver clinics
Country Year Sample
size
Mean age 
(years)
Mean duration 
infection
Cirrhosis
prevalence
Italy “ 5 1997 429 50 Unknown 25.4%
Germany 146 1997 187 43 Unknown 15%
Italy 147 1998 96 47 Unknown 16.7%
USA «2o 1997 50 51 Unknown 14%
U K 14« 1995 42 37 13 years 4.7%
Europe 5 1998 292 49 11 years 24%
Spain 149 1998 253 43 Unknown 6.4%
Japan 166 1990 205 54 Unknown 35%
Germany 152 1998 838 49 10 years 16.8%
France (OBSVIRC Group) 154 1997 1138 44 11 years 12.5%
France (DOSVIRC Group) 154 1997 607 46 14 years 17%
France (METAVIR Group) 154 1997 490 49 Unknown 31%
Australia159 1995 152 36 Unknown 32%
Japan136 1993 333 49 19 18%
USA161 1995 131 57 22 51%
UK165 1997 140 36 Unknown 7%
Tong et reported on 131 patients with chronic post transfusion HCV referred to a tertiary 
liver centre with chronic liver disease. The mean age at transfusion was 35 years and 57 years at 
the time of assessment. The mean period of follow up after referral was 3.9 years (range 1 to 
15). On assessment, 46% of the subjects had cirrhosis and 10.6% had HCC. The mean interval
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between the time of transfusion to diagnosis of chronic hepatitis was estimated at 13.7 years 
(range 1 to 42), to cirrhosis of 20.6 years (range 3 to 42) and to HCC of 28.3 years (range 8 to 
42). Kiyosawa et studied outcomes in 231 subjects, and reported similar intervals for 
progression of disease i.e. a mean interval between the date of transfusion to chronic hepatitis, 
cirrhosis and HCC of 10, 21 and 29 years, respectively. In a subset that underwent successive 
liver biopsies, sequential progression through chronic hepatitis and cirrhosis to HCC was 
observed.
Poynard et assessed the natural history of liver fibrosis in three sets of subjects (n=2,235). 
They identified an estimated median duration of infection to cirrhosis of 30 years, ranging from 
13 years in men infected after the age of 40, to 42 years in women who did not drink alcohol 
and were infected before the age of 40 years. They estimated than in 20 years, over one third of 
subjects would progress to cirrhosis, but that a further third would not progress for 50 years or 
never progress. The independent factors that were associated with progression, were age at 
infection of over 40 years, alcohol consumption greater than 50g per day and male sex.
Takahashi et aZ36 studied 333 Japanese subjects with chronic hepatitis and observed a mean 
time interval of 12 years from blood transfusion to histological diagnosis of chronic persistent 
hepatitis, and of 24 years to liver cirrhosis.
An Australian study studied 342 patients referred to a liver clinic of which 53% were IDUs.
The median age of this group was 33 years (range 14 to 47). This group estimated a median 
time from first exposure to a risk factor for HCV infection to cirrhosis of 18 years (range 5-48), 
and to chronic hepatitis of 13 years (range 1-26).159
The principal problem with such studies is that as they report on those with established liver 
disease they focus on the more severe end of the disease spectrum and may therefore over­
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estimate rates of progression and frequency of liver pathology. Accurate data on the duration 
of infection is lacking and the majority of studies estimate disease duration by extrapolating 
backwards to the time of first risk exposure. As they do not include those with asymptomatic 
HCV or those with established dates of acquisition of infection they cannot give estimates of 
rates of progression to sequelae. What such studies do provide are estimates of disease 
progression in those with established liver disease, although as they report on the shortest time 
period to development of severe outcomes such estimates are also biased.
Fattovitch et a l132 reported on the outcome after development of cirrhosis in 384 patients with 
compensated cirrhosis. During a period of 50 months follow up, 9% of patients died from liver 
related causes. Survival probability was 96% at 3 years and 91% at 10 years unless 
decompensation occurred in which case survival dropped to 50% at five years. Two hundred 
and five patients (53%) were treated with interferon and after adjustment the 5-year estimated 
survival probability was 96% and 95% for treated and untreated patients, respectively.
2.4.2.4 Population Based Longitudinal Studies
Population based or community studies involve subjects, followed up prospectively, who were 
not known to have underlying disease at the time they were identified being anti-HCV positive. 
In such studies the date of exposure is clearly established and in only a minority of cases is the 
exposure route transfusion of contaminated blood (Table Z i).7475 144 167-171
Table 2.5 Progression to cirrhosis in population based studies of community acquired HCV 
infection
Country Dominant 
transmission route
Sample
size
Mean age 
(years)
Mean duration 
infection
Cirrhosis
prevalence
Sweden167 IDU (75%) 10 54 29 20%
Germany168 Anti-D IG (100%) 74 34 10 0%
Denmark169 Unknown 178 51 23 9%
Ireland 75 Anti-D IG (100%) 390 45 17 1.9%
Sweden 144 Unknown 24 41 13 8.3%
Germany 74 Anti-D IG (100%) 917 44 20 0.4%
USA 171 Unknown 17 65 45 5.8%
Austria 172 Plasmapheresis (100%) 20 42 18 20%
In 1999 the Irish Hepatology Research Group reported on 17 year follow up of women who 
had been infected with HCV through contaminated anti-D immunoglobulin in 1977/78.75 Of a 
total of 62,667 screened, 704 were anti-HCV positive, and of these 390 (55%) were also 
positive for HCV RNA (all genotype 1), indicating a high overall level of clearance of infection. 
Assessment of those chronically infected revealed normal ALT levels in 45%. Liver biopsy in 
this group indicated that about half had evidence of hepatic inflammation, but of these only 15 
%  had bridging fibrosis and only 2% had probable or definite cirrhosis. Two of the seven 
subjects with cirrhosis reported excessive alcohol consumption. This contrasted considerably
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with estimates from liver clinic and transfusion studies of 20% progression to cirrhosis at 20 
years.
Similar data were obtained from an East German study that reported on 1,018 women 
followed for 20 years after receiving contaminated anti-D.74After 20 years, 85% were still anti- 
HCV positive, although only 55% were HCV RNA positive. Only 4 (0.4%) had overt cirrhosis 
of whom 2 had died, one of fulminant hepatitis B and the other of cirrhosis secondary to 
alcohol dependence. Histology obtained in 44% of the viraemic women demonstrated hepatitis 
of minimal to moderate grade in 96%, and septal fibrosis in 3% of the cases.
Both these studies have low rates of progression to cirrhosis and appear to support the opinion 
that women infected with HCV at a young age have a low rate of progression to cirrhosis. 
However, although these studies are informative, the natural history of HCV in women 
infected through contaminated anti-D may not reflect the natural history of HCV acquired 
through other routes, in particular IDU. In the former case all women were infected with one 
genotype (lb) on one occasion only, which does not reflect the pattern in IDUs of multiple 
small exposures to different HCV genotypes.
Three further population based studies that involved small numbers of subjects have reported 
varying outcomes after infection with HCV. However the relatively low power of such studies 
limits the usefulness of study findings.
A study from Austria reports outcomes in 20 of 30 subjects infected with HCV (all genotype 
la) at a plasmapheresis centre in 1977/78.172 The mean age at time of infection was 24 years 
and 90% were male. Assessment after 18 years in this group indicated that 20% had cirrhosis.
A further study with similarly small numbers reports on 29 subjects identified as anti-HCV 
positive through testing of stored sera from 1969 to 1972.167 At 25 years follow up, 4 had died
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(only one from liver related causes) and 15 were untraceable. Of the remaining 10 cases none 
had overt cirrhosis.
Seeff et a l report on the outcome of HCV infection in a group of male airforce recruits who 
had blood stored between 1948 and 1954.171 Stored samples were obtained for 8568 subjects 
and 17 (0.2%) tested anti-HCV positive -  of whom 11 were also HCV RNA positive. Follow 
up revealed that 7 subjects had died (only one of liver disease) and among the 10 remaining 
alive, liver disease had been identified in only 1. The numbers involved are extremely small, 
but indicate that mortality and morbidity from liver disease in these groups are probably low.
2.4.2.5 Studies in Blood Donors
Several studies in blood donors found to be anti-HCV positive during pre-donation screening 
support the picture of a more benign course of HCV. Alter reports on 248 asymptomatic anti- 
HCV positive blood donors followed prospectively. Among 81 patients who underwent liver 
biopsy, only 13% had evidence of severe hepatitis (8%) or cirrhosis (5%), despite a duration of 
infection that generally exceeded 15 years.173 Shakil et a l enrolled 60 anti-HCV-positive blood 
donors into a prospective study.174 Mean duration of infection was 19 years and only 2% had 
evidence of cirrhosis. Rates of progression to cirrhosis are low in both studies, although both 
estimated duration of disease as the length of time from first exposure to an identified risk 
factor and may therefore have overestimated the duration of disease.
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2.4.3 Factors Influencing Progression of Disease
It is emerging that end-stage liver disease is not an inevitable consequence of HCV infection 
and that only a subset will develop progressive disease. A number of factors appear to 
influence progression of disease although their precise role remains unclear. These factors 
include viral factors (genotype, viral load), host factors (age at infection, duration of infection, 
gender, genetic susceptibility, co-infection with other viruses in particular HBV and HIV, co- 
morbid medical conditions such as iron overload) and external factors (excess alcohol, diet, 
smoking, medicines, hepatotoxins or undefined environmental contaminants).175
2.4.3.1 Genotype
The association of viral genotype with outcome is unclear. Many studies have found that 
genotyope lb  is associated with more severe disease than other genotypes although such 
studies may be confounded by length of infection. In many countries the distribution of 
genotypes varies with the age of the subjects, possibly reflecting the introduction of genotypes 
through different routes of infection such as IDU. In general those who contracted HCV via 
transfusion were more likely to be infected with subtype lb , whereas IDUs tend to be infected 
with 3a.5 146 Consequently there is a trend that younger people are more likely to be infected 
with subtype 3a, and older people with subtype lb .48 Cirrhosis has been documented in 
subjects with all genotypes and there does not appear to be a non pathogenic genotype.
Pozzato et a/116 were among the first to report a link between genotype and cirrhosis when they 
compared genotypes from Italian and Japanese patients with HCV. They found genotype lb  
was more commonly associated with cirrhosis, but as most subjects (74%) were genotype lb  it 
made comparison with other genotypes difficult. Kobayashi et aZ177 followed 100 patients with
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genotype 1, and 36 with genotype 2 over 8 years, and found that those with genotype 1 were 
more likely to have higher HCV-RNA titres, greater deterioration of liver histology' and 
development of HCC. Zein et a/178 examined explanted livers for the presence of HCC and 
found that 5 of 18 patients infected with genotype lb  (28%) had HCC, but only one of 30 
patients (3%) infected with all other genotypes (la , 2a, 2b, 3a, and 4a) had HCC. Gordon et 
afl19 found that Genotype lb  appeared to be associated with a higher degree of post liver 
transplant fibrosis and cirrhosis than non-lb genotypes.
However other studies have found no association between genotype and adverse outcomes5180 
and indeed it is difficult to interpret the influence of HCV genotype on the progression of 
disease from cross sectional clinic based studies with only approximate data on duration of 
disease. One study found that while genotype 1 was significantly more common in patients 
with cirrhosis, in multivariate analysis the effect disappeared and the only factors associated 
independendy with cirrhosis were older age at exposure and longer duration of infection.181
However, a large prospective study of 163 patients with cirrhosis identified that those with 
genotype lb  were significantly more likely to develop HCC and similar findings were reported 
in two case control studies,133 182 although two other prospective studies found no 
association.134145
It remains controversial whether genotype does influence outcome of disease and it is likely 
that confounding factors make interpretation of studies difficult. Such confounding factors 
include age, duration of infection and lifetime alcohol consumption.
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2.4.3.2 Age
Age at infection is strongly associated with progression to adverse outcomes such as cirrhosis 
and HCC. Age has also been associated with reduced ability to clear the virus following 
infection.
Vogt et rf/183 reported on 67 German children infected with HCV by contaminated blood during 
cardiac surgery before 1991. Their mean age at first operation was 2.8 years. At follow up a 
mean of 19.8 years later, 37 (55%) of the 67 who were positive for anti-HCV had detectable 
HCV RNA in their blood. Only 1 of the 37 had elevated levels of liver enzymes and that 
patient had severe right-sided congestive heart failure. Of the 17 patients who underwent liver 
biopsies, only 3 had histological signs of progressive liver damage and these 3 had additional 
risk factors: two had congestive heart failure, and the other active HBV infection. The authors 
concluded that the clinical course of those infected as children seems more benign than would 
be expected in people infected as adults. However the impact of HCV on such children as 
they age is as yet unknown. Similar findings are reported by Locasciulli et a/1*4 who report on 
114 subjects cured of childhood leukaemia followed prospectively for at least 10 years since 
chemotherapy withdrawal. Forty subjects (35%) remained HCV-RNA positive and none 
developed signs or symptoms of decompensated liver disease.
In adults the mildest outcomes have been observed in those infected under the age of 40 and 
age has been reported in many studies to be a predictor of poor outcome.132 n? 154159185 m
Poynard et afl54 reported that age at infection of over 40 years old was independendy associated 
with progression of HCV related liver fibrosis (as was male gender and alcohol consumption). 
Khan et a l followed a cohort of 455 subjects with clinically compensated HCV for a mean
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period of 4.7 years and identified age among the independent factors associated with poor 
outcomes.186
The more benign course of disease in those infected as young adults was demonstrated by the 
anti-D immunoglobulin studies,74 75 and the adverse outcomes reported in studies of TA- 
NANBH could be due to the relatively advanced age of subjects at infection.142
The reasons for the apparent impact of age are unclear; it could represent infection with a 
possibly more virulent genotype, as there is a trend that younger people are more likely to be 
infected with subtype 3a, and older people with subtype lb ,8 although the impact of genotype 
on outcome remains unclear. The observed association could also be due simply to a longer 
duration of infection. It may also represent age related immune-based changes that lead to 
acceleration of disease in affected individuals. If this is the case, it could be that those infected 
at younger age would also demonstrate acceleration of the disease process as they age.
2.4.3.3 Gender
Male sex is associated with poorer outcomes from HCV, both from initial clearance of 
infection187 188 and long-term outcomes.125 186 189.
Poynard eta/154 described risk factors for fibrosis in 2235 patients and found that histological 
staging of fibrosis in men was higher than in women irrespective of age, duration of disease or 
alcohol consumption. Poorer outcomes in men have been reported in a number of other 
studies.186190
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2.4.3.4 Alcohol
The relationship between alcohol use and poor outcomes of HCV infection has been 
demonstrated in numerous studies.153 153 154 164 185 19o-19^
One retrospective study found a threefold increased risk of liver cirrhosis and decompensated 
liver disease in those with high alcohol intake (>50gms per day), and that the rate that subjects 
developed cirrhosis was faster in the high alcohol group compared to the non alcohol group -  
by the second decade 58% were cirrhotic, as opposed to 10% in the non-alcohol group.192
It is now widely accepted that HCV and alcohol are not only independent risk factors for 
chronic liver disease, but also act in combination to increase rates of progression to poor 
outcomes. The NHLBI study reported on the relationship between development of cirrhosis 
and alcohol abuse in 1030 subjects with TA-NANBH.193 The authors found that the risk for 
cirrhosis was 17% among subjects with HCV, and 2.8% among HCV negative controls. A 
history of heavy alcohol use (>125gms alcohol per day) was associated with a fourfold- 
increased risk of cirrhosis, but in those with a history of heavy alcohol abuse and HCV the risk 
of cirrhosis increased thirty-fold.
In another study of 6,917 subjects in a north Italian town, of those who were HCV infected 
and did not drink excessively 11.5% had cirrhosis, compared to 31% of HCV infected subjects 
who drank excessively.194
There is also a strong association between IDU and alcohol use. In one study over half of anti- 
HCV positive alcohol patients gave a history of IDU compared to 2% of the anti-HCV 
negative subjects.191In this group the combination of alcohol excess and HCV led to higher 
levels of chronic liver disease.
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2.4.3.5 Race
The impact of ethnicity on adverse outcomes of HCV is unclear. The majority of studies have 
been conducted in white populations, although one Australian study identified birth in Asia, 
the Mediterranean regions or Egypt as a risk factor for progression to adverse liver 
outcomes.186.
Black subjects have been observed to have reduced response rates to interferon monotherapy 
although the reasons for this are unclear.195 Thomas et a l assessed HCV viral clearance in a 
subset of 919 patients infected through IDU over a median period of 8.8 years. Viral clearance 
was observed in 90 (9%), 722 (78%) had persistent viraemia and in 107 (12%) viraemia was 
‘not resolved’. Viral clearance occurred five times more often in non-blacks although the 
reasons for this were not clear.
2.4.3.6 Co-infections
Co-infection with HIV
There is clear evidence of an increase in the incidence of chronic liver disease in HCV/HIV 
co-infected individuals compared to those with HCV alone. In one study the relative risk of 
HCV mono-infected haemophiliacs developing hepatic decompensation after 20 years was 
10.8%, rising 21-fold in HCV/HIV co-infected subjects.196 The authors concluded that HIV 
infection in those with HCV accelerates progression to cirrhosis and speculate this may be due 
to enhanced HCV replication in the presence of immune deficiency.
Eyster et a/197 reported on a prospective cohort study of subjects with haemophilia. In those co­
infected, 9% had liver failure after 10 years of HCV infection compared to 0% of HCV mono-
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infected individuals. In this cohort, co-infected subjects who survived for longer than 10 years 
had a risk of liver failure twice that of progression to Acquired Immune Deficiency Syndrome 
(AIDS), and mortality due to chronic HCV in HIV negative subjects was uncommon.
The main hypothesis for the increased risk of liver disease in co-infected individuals is the 
association with significandy higher levels of HCV viraemia,198 which in turn may correlate 
with increased liver damage. In one study, HCV-RNA levels increased 3-fold in those who 
were HIV-negative, whereas in co-infected individuals a 58-fold increase was observed during 
the same time period.198
Co-infection with HBV
There is a complex relationship between HBV and HCV. While HBV and HCV are 
independendy associated with the development of HCC, there is also evidence of a synergistic 
interaction between HBV and HCV and development of HCC.
Two studies from Taiwan, one a matched case-control study199 and the other a cohort study200 
examined the association between HBV and HCV in patients with HCC. Tsai et aP100 reported 
that HCV/HBV co-infection, anti-HCV alone, and HBsAg alone were independent risk factors 
of HCC and that the increased risk of HCC in patients with combined HBV and HCV 
demonstrated a linear trend compared to those without. Chuang et a/199 reported that both 
HBsAg and anti-HCV were important risk factors for HCC, but the risk for HCC was elevated 
significantly with combined HBV and HCV infection indicating an additive and independent 
effect modification of HCV and HBV infection on HCC development. An Italian prospective 
study of 290 patients with cirrhosis reported that age, positivity for HBsAg and HCV 
antibodies, male sex and previous alcohol abuse were independendy related to development of 
HCC.201 These studies suggest that there is an additive and independent effect modification of 
HCV and HBV infection on HCC development.
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There has been renewed interest in the impact of occult HBV infection in subjects with 
chronic HCV infection. Cacciola et a/202 demonstrated HBV DNA in 33% (66/200) patients 
with chronic hepatitis C liver disease. Among the 6 6  subjects, all were HBsAg negative, 46 were 
HBcAb positive and 20 were negative for all HBV markers. Thirty three percent (22/66) had 
cirrhosis, compared with 19% (26/134) of the patients with hepatitis C infection, but no HBV 
sequences. The authors concluded that occult hepatitis B infection occurs frequently in patients 
with chronic hepatitis C liver disease and may have clinical significance. The prognostic 
importance of low level HBV infection remains unclear however and other studies have failed 
to find an association between the prevalence of markers for HBV in those infected with HCV 
and the development of liver disease. 186
2.4.3.7 Other Factors
The dose of HCV at initial exposure varies by different routes of transmission. IDUs are 
exposed to multiple small doses of often varying genotypes, while transfusion recipients are 
usually exposed to a single large inoculum. Routes of HCV transmission have been shown to 
influence disease progression.
Gordon eta fi03 reported on blinded examination of liver histology' of 124 consecutive subjects 
referred to a liver clinic of whom 43 were blood transfusion cases and 40 intravenous drug 
users. All had similar durations of infection. The authors found that those with transfusion 
acquired disease had more aggressive histological inflammatory activities, even after allowing 
for the impact of age and gender. The implication from this paper is that the initial volume of 
viral inoculum may affect the severity of the initial pathological lesion, which in turn affects 
outcome although they may have underestimated duration of infection in subjects with IDU.
Similar findings have been reported in other studies, 156 204 although the results may be biased by 
factors including referral bias and unknown disease duration.
Genetic factors may also influence outcomes from HCV infection and studies have 
demonstrated an association between human lymphocyte antigen (HLA) alleles and outcomes. 
Several studies report that the class II DR and DQ alleles were found significantly more 
frequently in patients with spontaneous viral clearance compared to those with chronic 
infection.205-208
The association with HLA alleles and long term outcomes is less clear, but Kuzushita et aP** 
reported on 130 HCV infected patients and demonstrated that subjects with haplotype class 
1B54 were 13 times more likely to have liver injury than those without B54. However, liver 
injury in this study was based on serum ALT levels, which do not correlate well with 
histological activity.
Hypogammaglobulinamia has also been associated with poor outcomes from HCV.210 211 One 
study reported rates of progression to cirrhosis of 35% after 10 years.211 The immuno­
suppression associated with HIV also influences outcomes and although there is a correlation 
with low CD4 counts212213 the exact mechanism by which HIV adversely affects outcome is 
not known.
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2.5 Treatment
Interferon monotherapy has been used since the early 1990s to treat chronic HCV infection, 
but response rates were limited with high relapse rates. The introduction of combination 
therapy with ribivirin improved treatment outcomes, with approximately half of treated 
subjects achieving sustained viral clearance as measured by negative PCR test for HCV RNA at 
least 6  months after treatment. 10 9 A sustained virological response is associated with a 
prolonged biochemical and histological response.214 Factors that predict a good response to 
treatment include young age, female sex, minimal fibrosis on liver biopsy, low viral load and 
infection with genotype 2 or 3.215 216
Interferon therapy can be associated with severe side effects217and is not indicated in all 
patients, the difficulty lies in deciding who are appropriate candidates for treatment. Those 
with persistently normal liver function tests (LFT) and absent or only minimal changes on 
biopsy have an excellent prognosis without treatment. Therapy should be recommended for 
those at risk of progression -  i.e. persistendy elevated LFTs and fibrosis on biopsy. Patients 
who fall in-between the two extremes can be offered treatment or monitored with repeat LFTs 
and serial liver biopsies.216 218
The benefit of treatment in cirrhotics is less clear, although several studies have suggested that 
treatment with interferon in subjects with cirrhosis will reduce the risk of progression to 
decompensated liver disease and HCC. 134 219 138
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2.6 Quality of Life
Individuals with HCV complain of a number of non specific symptoms such as fatigue, 
irritability, headache, nausea and right upper quadrant pain which are not always related to 
objective evidence of liver or other disease. 121 There have been a number of studies which 
report broadly impaired health related quality of life (QOL) in subjects with chronic HCV 
which improves with successful interferon treatment, although the mechanisms underlying this 
impairment remain far from clear.
Foster et al. 220 reported Short Form 36 (SF-36) scores in 72 non-cirrhotic patients with chronic 
HCV and found them reduced across all modalities. Scores were also significantly less when 
compared to subjects with chronic HBV. The reduction in QOL in the HCV group could not
X
be attributed to the degree of liver inflammation or to the route of infection.
Hunt et al. 221 used the SF-36, the Beck Depression Inventory and the Hospital Anxiety and 
Depression Scale in a small study of 38 patients with chronic HCV and found reduced QOL 
scores pre-treatment with interferon. They also report that the presence of cirrhosis did not 
influence scores on any of these scales and that there were no differences in QOL after 
interferon treatment completion between responders and non-responders.
Bonkovsky et a l222 measured QOL at baseline and at the end of interferon treatment in 642 
subject with chronic HCV. Baseline data indicated that compared to normal controls, subjects 
scored poorly on all eight scales of the SF-36. Scores significantly improved in those who 
responded successfully to interferon therapy.
The reasons for reduced QOL in those with HCV are unclear. It is possible that biological 
mechanisms related to HCV account for low QOL, and this hypothesis is supported by studies 
that found that QOL improved in those with sustained biochemical or virological response to
interferon compared to non responders.222 224 While it is likely that diminished QOL in chronic 
HCV is, at least in part, a consequence of the disease, the positive psychological impact of 
being ‘cured’ of HCV was not accounted for in these studies.
A recent study investigated whether HCV could cause a cerebral effect and found elevations in 
basal ganglia and white matter choline/creatine ratios in patients with histologically mild HCV, 
compared with healthy volunteers and patients with HBV. This elevation was unrelated to 
hepatic encephalopathy or a history of IDU. 225 The clinical relevance of such a finding remains 
unclear.
Most QOL studies are from tertian’ liver centres, whose patients encompass the more severe 
end of the HCV disease spectrum. Such studies do not include those with milder or 
asymptomatic disease.
The effect of co-morbidities such as alcohol abuse or IDU could also contribute to the 
observed reduction in QOL in subjects with HCV, as both are independently associated with 
reduced QOL and psychiatric co-morbidities. 226 227 228229 However, Foster et a l720 found that 
although IDUs had the lowest QOL scores, scores were also reduced in those with no history 
of IDU. In addition, Fontana et al™  reported on 107 subjects with chronic HCV -  
approximately half of whom had a history of IDU -and found that a history of alcohol abuse or 
IDU did not correlate with reduced QOL scores, although having one or more active medical 
co-morbidities did.
It is likely however that psychological factors play a role in the reduced QOL of HCV patients. 
One study 231 investigated fatigue and psychological disturbance in subjects with chronic HCV 
compared to other chronic disease groups. They report that fatigue experienced by subjects 
with HCV is more severe and responds poorly to relieving factors, and that subjects with HCV
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harboured greater feelings of anger and hostility compared with those with non-liver chronic 
diseases.
In all QOL studies, subjects had been diagnosed and were aware that they had HCV. It may be 
that subjective health perceptions had been influenced by diagnosis of HCV alone which 
caused individuals to view their health related QOL in a less positive light. In order to 
investigate the impact of diagnosis it is necessary to measure QOL prior to imparting the 
diagnosis of HCV. We were able to undertake this in our study due to the availability of stored 
sera.
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CHAPTER 3: METHODS
3.1 Study Dqgign
A historical cohort study design was chosen. The exposure of interest was anti-HCV in 
archived stored sera from individuals admitted with clinical hepatitis to the Fairfield Infectious 
Diseases Hospital (FIDH) in Melbourne during the years 1971 to 1975. Individuals whose sera 
tested anti-HCV positive formed the exposed cohort, and those testing anti-HCV negative the 
unexposed.
Relevant study outcomes were mortality, liver-related morbidity (chronic hepatitis, cirrhosis 
and HCC) and QOL.
3.2 Identification of Cohort Sampling Frame
In Melbourne, in the 1960s and 1970s, all cases of clinical hepatitis were admitted to the 
Infectious Diseases Hospital at Fairfield. From early 1970 it became standard practice to 
systematically store sera from all cases of hepatitis admitted to the hospital. The aim of this 
practice was to create a sera archive for future research purposes. The sera was frozen at <40 
degrees centigrade and retained on site at the hospital. This practice continued until the early 
1980s.
We decided to retrieve and test sera from the period 1971 to 1975 as it was the earliest point 
that systematic storage of sera began and also a previous study had identified anti-HCV in 
samples of the stored sera from that time.232 In addition coding using the International 
Classification of Disease - 9th version (ICD-9) was introduced to FIDH in 1970. This
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standardised the diagnostic coding of patients allowing for accurate identification of those 
admitted with hepatitis.
Discharge records for FIDH for the years 1971 to 1975 were obtained. All persons admitted to 
FIDH with a clinical or biochemical diagnosis of acute viral hepatitis from 1/1/71 to 31/12/75 
were included in the cohort sampling frame. Exclusion criteria included those without an 
original serum sample for testing and those for whom no medical record could be located. 
Those aged under 16 years at the time of admission were also excluded as their admission was 
generally precipitated by HAV, which was endemic at this time. 233
The original hospital records were obtained and details of the admission transcribed. 
Information obtained (Table 3.1) included clinical information, diagnosis on discharge, results 
of any serological testing undertaken and risk factors for blood borne viruses, if available.
Table 3.1 Data transcribed (if available) from the original FIDH medical records 
General
FIDH unit record number, date of admission, date of discharge and sera number 
Sociodemographic
Surname, first given name and second name (if any) on admission 
Date of birth, age at admission, gender, occupation and country of birth 
Full address (including postcode) and telephone number 
Next of kin details including name, full address and telephone number 
Risk factors for blood borne viruses in the six months prior to admission
Transfusion of blood or blood products, renal dialysis, tattooing, injecting drug use, 
occupational exposure, recent surgery, contact with a case of hepatitis, overseas travel 
Diagnostic data (ICD-9)
Original discharge diagnosis, other diagnoses 
Test results
Hepatitis Australia antigen, hepatitis A IgM, hepatitis B surface antigen, hepatitis B surface 
antibody, hepatitis D (delta) antibody
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3.3 Ethics
3.3.1 Ethical Approval
Ethical approval for the study was sought and obtained from Ethics Committees at all sites 
involved in the study - FIDH, the Alfred Hospital and the Australian Institute of Health and 
Welfare (AIHW).
The Ethics Committees required resolution of a number of issues prior to granting full ethical 
approval. The ethics of testing sera for HCV without the consent of the individuals from 
whom the sera was originally taken was considered, but all Committees deemed it to be in the 
individual and public interest that such testing was undertaken and the individuals traced and 
assessed if possible. Guidelines about the manner of making initial contact with subjects and 
how information was released to them at that contact were prepared and approved.
The ethics of undertaking a liver biopsy for study purposes alone, when it was not clinically 
necessary was also discussed. It was decided, under the guidance of the Ethics Committees, not 
to request consent for a liver biopsy for histological assessment of the degree of liver 
involvement if it was not clinically relevant to the ongoing care of the individual.
3.3.2 Informing Study Subjects of Anti-HCV Status
As routine testing for anti-HCV only became available in the early 1990s, it was likely that 
many of the identified anti-HCV positive subjects were unaware of their serostatus. This was 
particularly likely in those who had remained asymptomatic.
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In conjunction with the Ethics Committees it was decided that at the time of recruitment, 
subjects should only be told that the study was looking at outcomes in persons who had been 
admitted to hospital with ‘hepatitis' 25 years ago. The results of testing of the archived sera 
were not disclosed at this time. This was principally because tracing and recruiting subjects to 
the study was performed via telephone and letter — mediums deemed inappropriate to discuss 
sensitive and potentially very distressing material.
Subjects were sent and then completed the study specific questionnaire and the QOL 
questionnaire. Once the study centre received both, clinical review was arranged. It was at this 
point in the study that the examing physician informed subjects that they had tested anti-HCV 
positive on stored sera (to those affected that were unaware of their HCV serostatus) and that 
they could be chronically infected. Blood results and other investigations were also undertaken 
at this time.
This approach was taken to obtain current anti-HCV status, HCV RNA by PCR and LFT 
results to allow appropriate counselling as to current health status, degree of infectivity and 
their likely prognosis. Facilities were also available for subjects who wished to undertake more 
formal or prolonged counselling.
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3.4 Measurement of Exposure
3.4.1 Definition of Exposure
The exposure was defined as an anti-HCV enzyme linked immunosorbent assay (ELISA) 
Optical Density (OD) to cut off ratio of greater than 2 in archived sera from 1971 to 1975. 
Individuals who had OD ratios of less than one were classed as unexposed.
Previous studies of frozen sera stored for long periods suggested a more stringent classification 
was required to avoid overestimation of the prevalence of anti-HCV. 234 This was a problem 
particularly with first generation immunoassays and although second generation assays (as used 
in this study) are more specific we used twice the manufacturers recommended cut off, as 
recommended in the literature, 234 to further increase specificity of a positive anti-HCV test 
result. This point was also chosen because there was a bimodal distribution of results in our 
study (Figure 3. /).
Figure 3.1 Log scale of ratio of sample anti-HCV ELISA optical density (OD) to 
recommended cut off OD in stored sera samples (n=1511)
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Individuals with weakly positive results, i.e. sample ELISA to cut off OD ratio of 1-2 (n=99), 
were recorded as equivocal and excluded to minimise misclassification bias.
3.4.2 Testing of Stored Sera from 1971 to 1975
Multiple serum samples were stored for admitted patients between 1971 and 1975. Each 
sample had the subject’s name and hospital number attached and samples were stored in 
chronological order. The last available serum sample from each patient associated with their 
final hepatitis admission and which was adequate for testing was selected for each individual 
and obtained from storage. This was to allow maximum time for seroconversion to occur.
Serology was performed on the stored sera for all hepatitis markers using commercially 
available immunoassays: hepatitis A IgM (HAIgM) (IMX Assay and EIA Assay-Abbott 
Diagnostics, Abbott Park, Illinois, USA), hepatitis B core antibody (HBcAb) (RIA - CORAB), 
hepatitis B surface antigen (HBsAg) (RIA - AUSRIA II, Abbott Diagnostics) and hepatitis C 
antibody (anti-HCV) (EIA second generation assay - Abbott Diagnostics). Testing was 
conducted by the Victorian Infectious Diseases Reference Laboratory (VIDRL) and the 
National Serology Reference Laboratory (NRL), Australia. The laboratories designated results 
as reactive or non-reactive. All results were entered into an ACCESS database.
VIDRL also undertook PCR testing on anti-HCV positive stored sera, but only one sample was 
HCV RNA positive. HCV RNA is unstable, so correct handling and subsequent storage of the 
samples at -80 degrees C is essential to avoid false negative results. 235 The most likely 
explanation for non-detection of HCV RNA in our stored study samples is deterioration of 
HCV RNA due to the age of the samples, inadequate storage and recurrent freeze thaw cycles.
64
3.4.3 Quality Control of Sera Testing
The NRL was established in 1985 to develop a comprehensive quality assurance programme 
for laboratories undertaking HIV, HTLV and subsequendy, HCV serology. Components of the 
program include performance evaluation, specificity monitoring, quality control and quality 
assessment programmes. The NRL has gained certification/accreditation for its Quality 
Management System and is accredited to ISO Guide 25 and certified to the ISO9001 standards. 
The Victorian Infectious Diseases Reference Laboratory (VIDRL) uses the quality control 
mechanisms developed by the NRL.
Quality control (QC) samples are produced by the NRL for use with anti-HCV and HBsAg 
serological assays as well as with HCV nucleic acid testing and PCR assays. The QC samples 
are used in every assay run to confirm that test results are accurate and reliable. The NRL 
provides a mean and standard deviation for each QC batch which laboratories use as a guide 
for setting their validation limits.
In addition, quality assessment programmes are used to assess the accuracy of the entire 
laboratory testing process from receipt of the specimen to delivery of the result. A panel of 
unknown specimens (including anti-HCV positives, negatives, duplicates and replicates) are 
supplied from the NRL to a laboratory such as VIDRL, with instructions that the samples are 
handled and assayed according to normal procedures, the results are then audited.
In addition, the results of testing of the study stored serum samples were compared to original 
recorded results for HBsAg using Kappa to measure agreement. Ten subjects who had 
equivocal anti-HCV results were randomly selected, traced and current anti-HCV status 
determined to assess the impact of misclassification in these subjects.
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3.5 Construction of the Cohort
Stored serum of 238 patients was strongly reactive - greater than twice the standard cut-off - 
for anti-HCV, these formed the exposed group and all were selected for follow up. A random 
sample (n= 476) of the anti-HCV seronegative individuals (the unexposed group) was selected 
using standard computer randomisation soft ware (Excel) to give a 2:1 ratio of unexposed to 
exposed subjects.
The subjects contact information from the time of admission was transcribed from the original 
medical records from 1971 to 1975 and used for tracing purposes. This included hospital 
number, surname and given names as recorded, title, date of birth, address at time of 
admission, telephone number at time of admission, next of kin contact details (name, address, 
telephone, relationship), general practitioner (GP) at time of admission and date of admission. 
The individual’s occupation and any risk factors for blood borne viruses (BBV) - e.g. IDU, 
tattooing or blood transfusion - recorded in the medical history were also documented (Table 
3.1).
The public access electoral roll was obtained from the electoral office on microfiche and gave 
alphabetical listings of the complete electoral roll by surname with full name and address. 
Voting is compulsory by law in Australia and as a result the voting register is more 
comprehensive and up to date than that of other countries such as the UK. The electoral role 
does not however give date of birth. An electronic telephone directory (‘Oz on Disc1) was 
purchased and gave the ability to search on any field (given name, surname, address, and 
state) . 236 Similar search tools are available on the World Wide Web, but do not have the 
flexibility of commercially available products and their use is limited in studies such as this.
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Records were entered onto an ACCESS database and the tracing methods used on each 
participant and the number of searches required to determine the current address or contact 
telephone number documented.
Tracing was undertaken initially by matching full names on the electoral roll, followed by 
searching for a telephone number to match the electoral roll address on electronic telephone 
directory. If a matching telephone number was located, the individual was contacted by phone 
and asked if they were the person and asked to verify their date of birth. Protocols were 
prepared to deal with telephone contacts. To protect confidentiality, no details about the study 
were released until the subject had confirmed their name and date of birth. At this stage very 
brief details of the study were released -  that is the study was a follow up review on subjects 
admitted with hepatitis between 1971 to 1975. Subjects were asked if they would consent to 
take part and an information pack - including a consent form - sent to subjects {Appendix /). It 
did not reveal the results of testing of the stored sera or that serum had been tested. This 
information was only released at the time of clinical review. Figure 3.2 outlines the tracing 
algorithm used.
Study subjects located on the electoral roll, but for whom no contact telephone number could 
be located, were sent a letter with a request to contact the study centre if they were the named 
individual. No further information was given and ‘hepatitis’ was not mentioned in the letter. 
Subjects who contacted the centre received the same study pack as those identified by 
telephone contact.
Persons not found on the electoral roll were searched for on the aforementioned electronic 
telephone directory, particularly if they had uncommon surnames. The search then widened to 
location of next of kin recorded in the original medical records. This was performed in the 
same manner with initial searches on the electoral roll and use of electronic telephone
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directory. If a telephone number was found, the next of kin were contacted and asked if they 
could provide contact details for the named individual or pass on the study centre details with a 
request to call. If only an address could be matched, a letter was sent asking them to contact 
the study centre
Figxire 3.2 Study tracing algorithm
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Approaches to local doctors listed in the original medical admission records were also made to 
assess whether subjects were still attending the same practice. Other sources used included 
advertising in the national daily newspapers in the Public Notices Section on Saturdays for two 
weeks. Features were also placed in the Hepatitis C Support Foundation newsletter and study 
co-ordinators appeared on local state radio.
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Information was also obtained from the National Death Registry' maintained by the AIHW. 
Names and dates of birth were supplied to the registry who searched their database for a fee. 
This registry was computerised in 1982 and could not search before that date. We also 
purchased on microfiche the Victorian death index to 1985 and manually checked the years 
from 1970 to 1982.
When all other methods had been exhausted an application was made to the National Health 
Insurance Commission (NHIQ. The Commission -  which assisted with the study only as it 
was deemed to be in the individual and public health interest - searched their database to 
determine if study subjects had any contact with health services in the period from 
computerisation of records in 1982 to the present day. If subjects were located, the last 
recorded addresses on the database were supplied to the study for the exposed group, and a 
letter forwarded to the rest asking them to contact the study centre.
All study subjects located were invited to take part in the study by completing two postal 
questionnaires and, following completion of the questionnaires, to participate in follow up 
clinical examination.
No financial remuneration was offered to study participants at any point in the study.
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3.6 Assessment of Outcomes
3.6.1 Definition of Outcomes
The main outcomes measured were mortality, liver-related morbidity (chronic hepatitis, 
cirrhosis and HCC) and QOL.
Chronic hepatitis was defined as
■ histological evidence on liver biopsy of chronic hepatitis (based on HAI124), or
■ a serum hyaluronate level greater than 37pg/l, 237 or
■ ALT level >1.5 times upper limit of normal (NR 25-50u/l).
Cirrhosis was defined as
■ histological evidence on liver biopsy of cirrhosis (based on HAI124)) or,
■ a serum hyaluronate level greater than >2 0 0 |ig/l,237 or
■ clinical or radiological evidence of hepatic cirrhosis.
Hepatocellular Carcinoma was defined as
■ a hepatic space occupying lesion with a vascular appearance consistent with HCC on MRI, 
or
■ cytological or histological evidence of HCC on examination of liver tissue.
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3.6.2 Mortality Assessment
All causes of death including liver specific mortality data was obtained from searches of the 
Victorian and New South Wales State Death Registries and the National Death Registry 
maintained by the AIHW. For each subject in the cohort who was known to have died, a copy 
of the death certificate was obtained from the Victorian and New South Wales Death 
Registries. Coding for the underlying cause of death was by the ICD revision in use at the time 
of death. For deaths between 1971-1977, ICD- 8  was employed by the death registries and from 
1977 onwards, ICD-9 was used. For analysis, bridge coding of ICD revisions was conducted to 
give the corresponding ICD-9 categories in all cases
3.6.3 Morbidity Assessment
Morbidity data was collected through a self-administered study specific questionnaire {Appendix 
2) and a clinical proforma {Appendix J). The process of assessment was identical for both 
exposed and unexposed subjects.
Self-Administered Questionnaire: The questionnaire was developed specifically for the study 
and piloted at the local liver clinic. Study subjects were sent the questionnaire by post at the 
same time as the quality of life questionnaire. Both were self completed and returned to the 
study centre again by post.
The questionnaire collected information on;
• Risk factors for blood bome viruses both before admission in the early 1970s - to ascertain 
the possible route of infection - and also after admission to determine risk behaviours 
which could have led to transmission of HCV to others.
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• Sociodemographic and lifestyle information (including detailed information on IDU 
history)
• Lifetime alcohol consumption — regular drinking habits and binge episodes —was obtained. 
The questionnaire collected information on the duration and amount of alcohol consumed 
in addition to the type of alcohol (wine, beer, spirits, other)
• Other factors which could influence the natural history of the disease such as smoking, 
diet, the use of prescription medications such as the oral contraceptive pill and non 
prescription medications such as anabolic steroids.
• General health and other medical history including liver related and non-liver related 
conditions
• Testing history for hepatitis A, B and C, the results of testing and carriage status if know.
• The management of HCV including contact with health services (whether GP or specialist) 
and treatment offered and accepted (including interferon +/- nbivirin and naturopathic 
medications)
Once the questionnaire had been returned to the study centre the participants were invited to 
undergo clinical examination. Clinical examination was carried out either by a doctor of choice 
(for those who lived interstate) or by the study co-ordinator (myself) through the cohort study 
centre at the Alfred Hospital.
Clinical Assessment: A standardised clinical form was developed for the examining doctor to 
record the clinical history, examination and investigation findings. The form was piloted 
through liver clinics.
The form included questions determining the subjects full medical history, risk factor 
assessment, treatment history and the results of relevant investigations (including serological, 
biochemical, histological and radiological). A sample of sera was also taken under controlled
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conditions. This was taken by study staff at the study centre and by enrolled laboratories for 
those assessed interstate and subsequently sent by courier to the study centre. This sample was 
used for virological assessment and for measurement of serum hyaluronate.
The following information was collected by the clinical assessment:
■ Clinical signs of chronic liver disease and portal hypertension (enlarged liver, spider naevi, 
gynaecomastia, testicular atrophy, bleeding disorders, oedema/ascites, caput medusa, 
varices and splenomegaly). The Child Pugh score was calculated from the relevant indices 
(Table 3.2). Child Class A was classed as a score of 5-6, Child Class B a score of 7 — 9, and 
Child Class C a score of > 9.
Table 3.2 Grading system for cirrhosis: the Child-Pugh score124
Score Bilirubin Albumin Prothrombin Hepatic Ascites
(g/dl) (g/dl) time (Sec) encephalopathy (grade)
1 < 2 0 >35 1-4 None Mild
2 20-30 28-35 4-6 1 -2 Mod
3 >30 <28 > 6 3-4 Severe
• Hepatitis serology including hepatitis A IgM (HAIgM), hepatitis B core antibody (HBcAb), 
hepatitis B surface antigen (HBsAg) and hepatitis C antibody (anti-HCV).
• Laboratory indicators including aspartate aminotransferase (AST)/ALT ratio, prothrombin 
index, albumin, bilirubin, platelets, alpha-fetoprotein (aFP)
• Serum hyaluronate (HA): Serum HA has been shown to be a sensitive and specific non- 
invasive marker of fibrosis.238 HA levels were measured by the HA laboratory at Monash 
University in anti-HCV positive participants at follow-up through analysis in triplicate by a 
radiometric competitive assay (HA test, Upjohn, Pharmacia, Uppsala, Sweden) based on 
the use of specific HA binding proteins (HABP) isolated from bovine cartilage. Intra- and
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inter-assay coefficient of variance was <4% and <5% respectively. Results greater than 
37|ig/l were considered elevated. 237
• Ultrasound (U/S) was performed if clinically indicated to assess development of collateral 
circulations, portal vein diameter, ascites, liver echotexture for homogeneity, hepatic length 
at right kidney and splenic length.
• Liver histology: Liver biopsy was carried out only if clinically indicated and the patient gave 
full consent. The relevance to the study was explained to each study subject and if any 
participant underwent biopsy at any time histological staging and HAI was obtained and 
recorded.
• Virology: Both qualitative and quantitative virological assessment were conducted by 
VIDRL. Qualitative PCR was carried out using the Roche AMPLICOR kit (Roche 
Molecular Systems, Branchburg, NJ). Subjects with HCV RNA positive samples were 
genotyped by the Innogenetic line probe assay (LIPA; Innogenetics, Ghent, Belgium) 239 or 
by direct sequencing and viral load quantified.
3.6.4 Quality of Life Assessment
All subjects completed the SF-36 scale (.Appendix 4) prior to clinical review at the same time as 
the study specific questionnaire.
The SF-36 was chosen as a generic and widely used quality of life instrument, which has been 
adapted for use in Australia. 240-243 j t ls a standardised medical outcome questionnaire 
consisting of thirty-six questions in eight subscales and two summary’ scales and is constructed 
for self-administration (in about 1 0  minutes) or for administration by a trained interviewer in 
person or by telephone. The SF-36 measures the following eight health concepts, which are 
relevant across age, disease and treatment groups:
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1 . limitations in physical activities because of health problems;
2 . limitations in usual role activities because of physical health problems;
3. bodily pain;
4. general health perceptions;
5. vitality (energy and fatigue);
6 . limitations in social activities because of physical or emotional problems;
7. limitations in usual role activities because of emotional problems;
8 . and mental health (psychological distress and well being).
The SF-36 survey has a standardised scoring system which yields a profile of eight health 
scores, a self-evaluated change in health status and two summary scales - a physical component 
summary and a mental component summary. Subscale scores range from 1 to 100, so each 
individual then receives a score that can be converted to a centile score with reference to 
‘standardised’ scores.
In this study, subjects were told at the time of recruitment that the study was looking at 
outcomes in persons who had been admitted to hospital with ‘hepatitis' 25 years ago. Subjects 
completed the QOL questionnaire at the same time as the study questionnaire. Once the study 
centre received both, clinical review was arranged. It was at this point in the study that the 
process of imparting the diagnosis of chronic HCV infection (to those affected who were 
unaware of their HCV serostatus) and the results of sera testing was commenced. In this way 
subjects were unaware of their anti-HCV status at the time of recruitment and hence 
completed all parts of the study, including the SF-36 questionnaire, without this knowledge. 
This approach was taken partly to assess the impact of knowledge of HCV diagnosis on QOL 
and also to allow appropriate counselling as to current health status, degree of infectivity and 
likely outcome.
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We compared the SF-36 scores of the exposed and unexposed cohorts to each other, and also 
to population norms for Australia.244
In order to ascertain the impact of a diagnosis of HCV on quality of life an additional analysis 
was undertaken in those who were chronically infected with HCV (i.e. HCV PCR positive), but 
who had no clinical liver disease or other conditions that could affect quality of life. Subjects 
were therefore excluded from this analysis if found to be currently anti-HCV or HCV RNA by 
PCR negative, have cirrhosis or clinically detectable liver disease, if symptomatic at the time of 
their recent anti-HCV testing or with other medical or psychiatric conditions which could 
affect quality of life.
We then examined the QOL scores of this subgroup of the subjects with long standing chronic 
HCV infection, only approximately half of whom were aware that they were HCV seropositive 
at the time the QOL scores were measured. To investigate the impact of HCV diagnosis on 
quality of life, we compared the scores between those aware of their serostatus and those not 
aware.
3.7 Data Management and Quality Control
Self completed questionnaires that were returned incomplete or with ambiguous entries were 
completed by trained study staff via telephone interview with subjects. If possible all questions 
were answered
Collection of clinical data was performed by a number of clinicians. All subjects attending for 
review in the study centre were seen by the study co-ordinator (myself) to minimise 
measurement bias. Where possible, interstate subjects were reviewed by specialist
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gastroenterology staff. The clinical proformas were reviewed and ambiguous or unclear items 
were rechecked with the examining physician.
All forms were identifiable only by the subjects study number and were stored in locked 
cabinets at the study centre. The forms were coded prior to data entry onto the database 
package ACCESS. A number of forms were created in ACCESS to facilitate data entry. These 
forms contained consistency and range checks to alert staff to data entry errors. A data 
dictionary was complied and contained a list of all variables, coding instructions, values allowed 
and the names of relevant computer files. Training was given to the two study staff who 
entered data.
Data entry errors were detected by double entry verification and by range and consistency 
checks once all data had been entered. Back up copies of the database were made weekly and 
one copy stored of site.
3.8 Statistical Analysis
Statistical analysis was performed with the Statistical Package for Social Sciences (SPSS) . 245 For 
each cohort member, person-years at risk were calculated from the date of the stored sera to 
the date of death or study follow up assessment. Cohort mortality data was compared to that of 
the general population. Expected deaths by cause in the cohort were calculated by multiplying 
the age, sex and year specific person years at risk within the cohort, by the corresponding 
national cause specific mortality rates. Standardised mortality ratios (SMRs) were then 
calculated by dividing the number of deaths in the cohort with the expected number and 
multiplying the result by 100. Confidence intervals (Cl) and 2-sided p-values were calculated 
based on the Poisson distribution.
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Morbidity outcomes were measured as binary responses or as continuous measures where 
appropriate. Exposures were measured as either binary or cumulative continuous during the 
entire cohort interval since the 1970s. Logistic regression analysis was used for binary 
outcomes and linear regression for continuous outcomes.
The impact of confounders (alcohol use, age, gender, co-infections and smoking) was 
controlled for through the use of multivariate regression analysis -  either linear for continuous 
outcomes or logistic for binary' variables.
Study subjects QOL scores were compared to population norms for Australia.244 Multiple 
linear regression analysis was used to compare SF-36 scores between groups based on 
knowledge of HCV sero-status after adjusting for recognised QOL confounding variables such 
as age, sex, marital status and ethnic group.
3.9 Power Calculations
Study power was limited by the ability to trace and recruit subjects through to completion of 
the study. The expected outcome rates and numbers of clinical end-points were based on the 
results of the pilot study.246 For chronic hepatitis we expected approximately 50% of subjects 
to be affected and for cirrhosis approximately 10%. The precision of absolute estimates was 
estimated for 100 subjects completing follow up, based on 95% confidence interval for rates. 
We estimated that on this number of subjects we could estimate the true value for chronic 
hepatitis (based on 50 events) to within plus or minus 30% and for cirrhosis (based on 10 
events) to within plus or minus 60%.
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CHAPTER 4: RESULTS
4.1 Identification of Cohort Sampling Frame
A ratal of 1,798 patients (aged greater than 16) were identified from FIDH discharge records as 
having been admitted from 1971 to 1975 with a diagnosis of viral hepatitis (ICD-9 
Classification 070.0 to 070.9). Medical records were found for 1,737 (97%). Five percent had 
been admitted with hepatitis more than once over the study period so the first admission was 
used as the index admission for study purposes. Serum specimens were found for 1559 (90%) 
of identified subjects and testing for all the measured hepatitis (HAIgM, HBcAb, HBsAg, anti- 
HCV) markers completed for 1,511 (87%).
4.2 Measurement of Exposure
4.2.1 Serological Analysis of Stored Sera (1971 to 1975)
Ninety-nine (7%) of the 1,511 cohort members had equivocal anti-HCV results (OD ratio 1-2) 
and were excluded from the study to minimise misclassification bias. A random sample of 12 
of these individuals were traced and found to be currently anti-HCV negative supporting our 
hypothesis that their equivocal anti-HCV results in the stored sera were borderline false 
positives.
Of the remaining 1,412 subjects, 238 patients had strongly reactive sera - greater than twice the 
standard cut-off - for anti- HCV. These formed the exposed group and all were selected for 
follow up. A random sample (n= 476) of the anti-HCV seronegative individuals (the 
unexposed group) was selected to give a 2 :1  ratio of unexposed to exposed.
79
The mean time from admission to FIDH to storage of the sera sample was significandy shorter 
for the anti-HCV positive group (mean 48 days, SD 54) compared to the anti-HCV negative 
group (mean 57 days, SD 58), (mean difference -8 .6 , 95% Cl: -16 to -1, p=0.027).
Fignre 4.1 Histogram demonstrating distribution of the interval (in days) between admission
to storage of sera sample for all cohort subjects with sera available for testing 
(n=1511)
T im e from admission to sera storage (days)
Only 15% (n=37) of those who were anti-HCV positive had no evidence of other hepatitis 
markers. Furthermore those who were anti-HCV positive were significandy more likely to 
have markers for HBV (Table 4.1).
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Table 4.1 Prevalence of markers of viral hepatitis infection in anti-HCV positive compared
to anti-HCV negative patients admitted to FIDH from 1971 to 1975
Anti-HCV positive 
(n=238)
Anti-HCV negative 
(n=1182)
RR (95%CI) p value
Anti-HAV IgM 14.3% 45.1% 0.2 (0.1 to 0.3) <0 .0 0 1
Anti-HBc 75.2% 42.6% 4.0 (3.2 to 5.6) <0 .0 0 1
HBsAg 45.7% 23.3% 2.7 (2.1 to 3.7) <0 .0 0 1
The trends in prevalence for each of the measured hepatitis markers were significant, the 
prevalence of anti-HCV increasing four fold from 1971 to 1975, with the biggest increase 
between 1974 and 1975. Increases were also seen in the prevalence of HBcAb and HBsAg.
The prevalence of anti-HAV IgM declined over the period studied (Figure 4.2). In those who 
were HCV seropositive the prevalence of markers of hepatitis A and B did not change 
significantly over the study period.
Figoire 4.2 Prevalence of markers of viral hepatitis (anti-HAV IgM, HBcAb HBsAg, anti-HCV) 
in stored sera from patients admitted to FIDH from 1971 through 1975
n = 318  n= 269 n = 259 n = 280  n= 286
Year o f adm ission
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4.2.2 Validation of Sera Testing Results
A comparison of study testing of stored sera for HBcAb and anti-HCV with the results of follow 
up (1997) serology in a traced subset of the original cohort (n=161) demonstrated that the overall 
agreement was good, with complete agreement for the former of 91% (Kappa 0.79 [95% Cl 0.67 
to 0.91]) and for the latter of 8 8 % (Kappa 0.74 [95% Cl: 0.66 to 0.82]).
There was moderate agreement when results for HBsAg recorded at the time of original [ )
admission were compared with our results of testing of the stored sera, with complete agreement 
for 65% (Kappa 0.58 [95%CI: 0.43 to 0.72]). .
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4.3 Characteristics of Cohort at Baseline
4.3.1 Sociodemographic Data
Sociodemographic data were available from medical case records for all subjects. The 238 anti- 
HCV positive individuals were significandy younger than anti-HCV negative individuals, 
(geometric mean age at time of original admission: 22 years [SD 5.3 yrs] and 29.5 years [SD 12 
yrs] respectively, p< 0.001). Those who were anti-HCV positive were also significandy more 
likely to have been bom in Australia than those who were negative (80% and 69% respectively,
(RR 1.5, 95% Cl: 1.4 to 1.8. p<0.001) and to be male (62% and 52% respectively, (RR 1.4, 95%
Cl: 1.1 to 1.9. p<0.001). U '
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4.3.2 Risk Behaviours for Viral Hepatitis
Information on risk factors was incompletely recorded in medical records. In total only 40% 
had recorded information for IDU, 69% for contact with a case of hepatitis, 36% for 
transfusion, 15% for tattooing and 1 1 % for travel.
A history of IDU and of contact with a hepatitis case were the only risk factors significantly 
associated with HCV sero-positivity (Table 4.2). There was good agreement between original 
recording of IDU in case records on admission and follow up information obtained from a 
subset of the cohort of IDU during that time (Kappa 0.83 [% Cl 0.74 to 0.92]).
Table 4.2 Proportion of anti-HCV positive and anti-HCV negative admissions to FIDH
(1972 through 1975) who have a positive history of a risk factor for blood borne 
viruses recorded in medical case records
Anti-HCV
positive
Anti-HCV
negative
RR (95%CI) p value
IDU 90.4% 22.3% 32.9 (19 to 56) <0 .0 0 1
Tattoo 46.7% 40.6% 1.3 (0.7 to 2.5) 0.49
Travel overseas 44.4% 73.5% 0 .2  (0 .1  to 1 .1) 0.08
Blood transfusion 17.9% 1 1 .2 % 1.7 (0.8 to 3.6) 0.11
Contact with a case 63.8% 35.2% 3.2 (2.3 to 4.6) <0 .0 0 1
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4.4 Construction of the Study Cohort
4.4.1 Tracing and Recruiting the Cohort
One person undertook the tracing over the three-year study period. This individual, a female, 
has enormous experience in tracing and recruiting for longitudinal studies. Tracing was 
undertaken on all members of the group and 64% of the exposed group (152/238) and 61% of 
the unexposed group (290/476) were successfully located (Figure 4.J).
Figure 4.3: Cohort subjects located and recruited to the study
The ease and success of tracing methods varied considerably. The most successful methods 
employed were search of the electoral roll/CD-ROM telephone directory and of the NHIC 
database, which located 36% and 33% of subjects respectively. Other less successful and time 
consuming methods were letter to last known address (15%), contact of next of kin (1 0 %), 
radio publicity (3%), newspaper advertisements (1%) and HCV support group newsletters, 
contact with last known GP or Svord of mouth’ (less than 1% each).
The proportion traced by any particular method was similar between the exposed and non­
exposed cohorts. Factors associated with successful tracing included being male, not admitting
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to a history of IDU at the time of admission in the 1970s and not having tattoos (Table 4.3). 
We found no difference in response rates by method of contact, in particular between those 
contacted by phone and those contacted by letter. A phone protocol had been developed, but 
was rapidly abandoned as each phone call was individual in nature.
The participation rate of those approached was 81% for the anti-HCV positive group and 84% 
for the anti-HCV negative group. Participation rate did not vary by method of contact, socio­
demographic features or risk behaviours (Table 4.4). Of those who did participate, 90% fully 
completed all aspects of the study, including clinical follow up.
Table 4.3 Socio-demographic and serological characteristics (at the time of original 
admission to FIDH in 1971 to 1975) associated with successful tracing
Proportion traced  (n=442) p value
Age (median=23)
>23 6 6 %
<23 60% 0.194
Sex
male 70%
female 55% <0 .0 1
Country of birth
Australia 65%
other 58% 0.158
History of IDU
no 80%
yes 65% <0 .0 1
HBcAb status
negative 65%
positive 61% 0 .2 2 1
Anti-HCV status
negative 63%
positive 64% 0.192
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Table 4.4 Socio-demographic and serological characteristics (at the time of original
admission to FIDH in 1971 to 1975) associated with participation in the study
Proportion participated 
(n=332)
p value
Age (median=23)
>23 82%
<23 83% 0.267
Sex
male 81%
female 85% 0.237
Country of birth
Australia 84%
other 78% 0.139
Tattooed
no 98%
yes 92% 0.713
History of IDU
no 95%
yes 81% 0.207
HBsAg status
negative 82%
positive 83% 0.785
HBcAb status
negative 87%
positive 78% 0.18
Anti-HCV status
negative 84%
positive 80% 0.482
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4.4.2 Completeness of Cohort Follow-Up
Almost two thirds of the cohort was located, 6 6 % of the exposed group (152/238) and 61% of 
the unexposed group (290/476). Of those located, 13% (20/152) of the former group and 7% 
(21/290) of the latter were deceased.
Of those who were located alive, 81% (n=107) of the anti-HCV positive group and 78% 
(0=225) of the anti-HCV negative group agreed at initial contact to participate in the study 
(Table 4.5). Follow-up was hilly completed by 98 anti-HCV positive (exposed) individuals and 
202 anti-HCV negatives (unexposed).
Table 4.5 Proportion of exposed and unexposed subjects who were located alive who 
participated in the study
Anti-HCV positive 
traced subjects (n=132)
Anti-HCV negative 
traced subjects (n=269)
Full participation in all aspects 98 (74%) 202 (75%)
of the study
Complete refusal to take part in any 25 (19%) 44 (16%)
aspect of the study
Partially completed the study 9 (7%) 23 (9%)
Seventeen unexposed subjects, whose 1971-75 sera were anti-HCV negative, were found to be 
anti-HCV positive at follow-up and excluded from further analysis to avoid misclassification 
bias. All results presented for the unexposed group from this point are based on the 185 who 
remained anti-HCV negative at follow up.
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Those completing follow-up did not differ sociodemiographically or serologically from the 
main cohort (Table 4.6).
Table 4.6 Comparison of the sociodemographic and serological characteristics at the time of 
admission to Fairfield Infectious Diseases Hospital from 1971 through 1975 of the 
study group with the full cohort by anti-HCV status
Anti-HCV positive
Full cohort Completing
(n=238) follow up (n=98)
Anti-HCV negative
Full cohort Completing follow
(n=476) up (n=185)
Median age (admission) 2 1  yrs 19yrs 30yrs 29 yrs
P roportion male 62% 65% 52% 54%
Barn in Australia 80% 81% 69% 77%
Hepatitis markers
Anti-HAV IgM 14% 15% 45% 58%
HBcAb 75% 75% 43% 33%
HBsAg 46% 49% 23% 17%
Anti-HCV only 16% 17% n/a n/a
4.5 Characteristics of the Cohort at Follow Up
4.5.1 Sociodemographic Data
Anti-HCV positive individuals (n=98) were significantly younger than those anti-HCV negative 
(n~185) (median age 44yrs </*52yrs, p=0.001), Table 4.7. Both seropositive and seronegative 
groups were predominandy male (65% and 54%) and bom in Australia (81% and 77%). The
highest level of education attained and current income level were similar between the two
groups. However, anti-HCV positive individuals were significandy more likely to be divorced 
(p<0.0001) and to receive sickness benefit as their main source of income (p=0.04) than those 
who were anti-HCV negative.
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Table 4.7 Sociodemographic data at follow up by anti-HCV status
Anti-HCV positive 
(n=98)
Anti-HCV negative 
(n=185)
p value
M ale (%) 64 (65%) 99 (54%) 0.56
M edian age in years 44 52 <0 .0 0 1
Education
Secondary 47 (48%) 76 (41%)
Tertiary 28 (29%) 63 (34%)
Trade 17 (17%) 32 (17%)
Other 6  (6 %) 14 (7%) 0.0428
Employment status (%)
Full time 46 (47%) 30 (43%)
Part time 1 0  (1 0 %) 18 (1 0 %)
Unemployed 6  (6 %) 10 (5%)
Sickness benefit 27 (27%) 23 (12%)
Other 9 (9%) 69 (34%) 0.04
Income level per year (%)
< $1 2 ,0 0 0 30 (31%) 57 (31%)
S12,001-525,000 28 (29%) 41 (22%)
$25,001-550,000 27 (28%) 48 (26%)
> $50,001 11 (1 2%) 37 (20%) 0.25
Marital status
Never married 17 (17%) 2 0  (1 1 %)
Married/defacto 47 (48%) 138 (75%)
Divorced 29 (30%) 19 (1 0 %)
Other 5 (5%) 7 (4%) <0 .0 0 1
Country of birth
Australia 79 (81%) 143 (77%)
Other 21 (19%) 42 (23%) 0.57
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4.5.2 Alcohol Intake
The exposed group was less likely to drink alcohol currendy than was the unexposed group 
(RR 0.6, 95% Cl: 0.4 to 0.8; p=0.03); however, this relative abstinence was only present in 
seropositive individuals aware of their HCV antibody status (n=52). Both groups had similar 
durations of alcohol intake, but the HCV positive group had consumed significantly greater 
average amounts of alcohol (mean 281gms per wk vs 123 gms per wk, p<0.001) over that 
period and were twice as likely to have had periods of 'binge' or dipsomaniac drinking (95% Cl:
1.5 to 2.2; p=0.02).
The overall consumption of alcohol was significantly higher in the exposed subjects who had 
progressed to clinically apparent cirrhosis (mean 844 gms per week [SD 252]) than those who 
hac not progressed (mean 312 gms per wk [SD 321], p=0.02).
4.5.3 Risk Factors for HCV Infection
Prior to admission to FIDH in the early 1970s, having a history of IDU conferred an increased 
risk of being HCV (RR 14.4, 95% Cl: 8 .6  to 24.5, p<0.001) Table 4.8. Eighty six percent of the 
anti-HCV positive group had injected drugs - two thirds doing so more than three times per 
week - for a mean period of 2 years prior to admission. Almost all (92%) shared needles.
A history of being tattooed also conferred an increased risk of being anti-HCV positive on 
admission (RR 2, 95% Cl: 1.6 to 2.9; p<0.001) as did a history of having unprotected sex. 
Receiving transfusions of blood or blood products, or being born overseas were not associated 
with HCV serostatus.
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Table 4.8 Risk behaviours for the transmission of blood borne viruses before admission to
Fairfield Infectious Diseases Hospital in the early 1970s
Anti-HCV
positive
(n=98)
Anti-HCV
negative
(n=185)
RR/Mean diff 
(95% Cl)
p value Adj.
RR*
p value
Blood transfusion (%) 5 (5%) 13 (7%) 0.71 (0 .3-1.7) 0.049
Tattooed (%) 2 2  (2 2 %) 12 (7%) 2.1 (1 .6-2.9) <0 .0 0 1 0.99 0.95
IDU (%) 85 (8 6 %) 3 (2%) 14.4 (8 .6  -  24.5) <0 .0 0 1 14.22 <0 .0 0 0
Mean duration yrs (SD) 2(2.5) 0.7 (0.7) 1.4 (.1.5 _ 4 .4 ) 0.043 1
% injecting >3/wk 70% 0 %
% sharing needles 92% 0 %
Unprotected sex (%) 91 (93%) 138 (77%) 2.7 (1 .4-5.6) 0.004 0.98 0.083
% one partner 14%
% > six partners 65%
’ Adjusted for IDU, Tattoo, and Sex -  two models used
In the period from admission to FIDH in the early 1970s to study follow up, anti-HCV 
positive subjects continued to be more likely to inject drugs (RR 8.4, 95% Cl: 5.7 to 12.3, 
p<0.001) than the anti-HCV negative group (Table 4.9). Seventy six percent of the exposed 
group injected drugs over a mean period of 9.5 years. Sixty three percent injected more than 3 
times per week and 73% shared needles.
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Table 4.9 Risk behaviours for the transmission of blood borne viruses after
admission to Fairfield Infectious Diseases Hospital in the early 1970s
Anti-HCV
positive
(n=98)
Anti-HCV
negative
(n=185)
RR/mean difif 
(95% Cl)
p value Adj.
RR*
p value
Tattooed (%) 25 (25%) 6  (3%) 2.8 (5.7 -  12.2) <0 .0 0 1 0.92 0.91
IDU (%) 74 (76%) 2  (1%) 8.4 (5.7 -  12.3) <0 .0 0 1 8 .6 <0 .0 0 0 1
Mean duration yrs (SD) 9.5 (7.9) 1.5 (0.7) 1.42 (-1.5-4.36) 0.37
% injecting >3/wk 63% 0 %
% sharing needles 73% 0 %
Unprotected sex (%) 98 (100%) 157 (85%) 3.8 (1.3-11.2) 0.016 1 .1 2 0.65
% one partner 14%
% > six partners 65%
•Adjusted for IDU, Tattoo, and Sex -  two models used
4.5.4 Hepatitis Testing History
In the period between discharge from FIDH to study follow up, the exposed group were 
significantly more likely to have undergone testing for the serological markers of hepatitis A, B 
and C (Table 4.10). In total, 56% (n=55) of anti-HCV positive subjects had been tested for 
anti-HCV prior to taking part in the study. The remainder (n=43) had not been tested and were 
therefore unaware that they were anti-HCV positive at the time of enrolment in the study. The 
8 % of the unexposed subjects who had tested for HCV had all tested negative.
Of diose in the exposed group who had previously and knowingly tested for hepatitis C, 94% 
(n-52) had been told they were anti-HCV positive. The 6 % (n=3) that tested ‘negative’ were all 
tested in 1991 and probably reflected a proportion of the false negative results that were 
obtained with first generation anti-HCV assays. All three subjects tested anti-HCV positive at 
the time of study follow up — using second or third generation assays.
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Three percent of the exposed group and 1% of the unexposed had been vaccinated against 
HAV. The proportions vaccinated against HBV were 5% in the exposed group and 7% in the 
unexposed.
Table 4.10 Proportion of the cohort who had undergone testing for serological markers of 
current or previous hepatitis A, B or C from the time of admission to FIDH to 
study follow up
Se rological marker Anti-HCV positive 
% tested
Anti-HCV negative 
% tested
p value
Hepatitis A 36% (35/98) 22% (41/185) 0.041
Hepatitis B 55% (54/98) 16% (30/185) <0 .0 0 0 1
Hepatitis C 56% (55/98) 8 % (15/185) <0 .0 0 0 1
4.5.5 HCV Treatment History
In those who were aware that they had HCV (n=52), only two had been treated with interferon 
(in 1993 and 1995) and none with interferon/ribivirin combination therapy. Both subjects had 
received interferon for less than 1 2  weeks in total, at dose of 1 million units three times per 
week. Neither had responded to treatment, both were currently HCV RNA positive and were 
genotype la.
Five subjects had tried homeopathic remedies such as milk thistle or silymarum for varying 
lengths of time. Most felt symptomatic benefit from this and had combined the treatment with 
abstinence from alcohol.
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4.6 Morbidity Outcomes
4.6.1 Serology
4.6.1.1 Unexposed (Anti-HCV Negative) Cohort
Seventeen unexposed subjects whose 1971-75 sera tested anti-HCV negative, were anti-HCV 
positive at follow-up and excluded from further analysis to avoid misclassification bias. Of 
these, 60% (n=10) had a history of IDU prior to admission to FIDH. The mean length of time 
subjects had been injecting was 9 months (SD 8.4). After admission to FIDH, 94% (n=16) 
admitted to a history of IDU for a mean period of 14 years (SD 25). Twelve subjects shared 
needles during this time. It is likely that subjects had become infected with HCV during this 
period of IDU after admission to FIDH.
The remainder of the unexposed group (n^ 185) remained anti-HCV negative at follow up.
Four unexposed subjects, who had been admitted with a clinical diagnosis of hepatitis B in the 
early 1970s, were HBsAg positive at follow up. Testing of stored sera indicated that three had 
been HBcAb positive at the time of discharge from FIDH. At follow up two also had HBeAg 
and DNA status measured, and were negative for both. Only one had an elevated ALT level, 
which was just above normal at 57 u/1 (NR 25-50 u/1)
Two unexposed subjects were HIV positive at follow up.
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4.6.1.2 Exposed (Anti-HCV Positive) Cohort
Seven exposed individuals, who were strongly anti-HCV positive on testing of stored sera from 
the early 1970s, were anti-HCV negative on follow-up testing, while a further subject had an 
equivocal result (with a previously positive anti-HCV result in 1996). This group (n=7, 7%), 
who were also negative for HCV RNA by PCR, appear to have ‘lost’ anti-HCV during the 
period 1971/75 to 1997/98, consistent with ‘natural’ clearance of HCV infection. None of 
these subjects had been treated with interferon therapy.
None of the anti-HCV positive group had evidence of chronic HBV infection (HBsAg) at 
follow-up.
One subject, who died in 1994 of cirrhosis, had HIV and HCV co-infection. None of the other 
exposed subjects were known to have HIV at follow up. HIV status was not routinely 
measured on study subjects due to ethical constraints. It is unlikely to be significant issue in this 
cohort as the risk of acquiring HIV through injecting drug use in Australia is very low27 and no 
exposed subjects were identified as homosexual.
4.6.2 Virology
PCR testing was completed in 97% (95/98) of anti-HCV positive subjects at follow-up. Fifty 
one (54%) of the anti-HCV positive group were HCV RNA positive indicating chronic HCV 
in fection. Genotyping was performed on HCV RNA positive samples. The most common 
genotypes and subtypes were 3a (45%), followed by la  (24%), lb  (10%) and 2b (9%). Another 
6 % of samples were genotype 1, but could not be further subtyped by the Innogenetics assay.
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Thus at follow up, 7% of the exposed cohort had unequivocal (anti-HCV negative) resolution 
of HCV infection, 42% had probable resolution (anti-HCV positive, but HCV RNA negative), 
while 51% were chronically infected with HCV (anti-HCV and HCV RNA positive).
Risk Factors for Chronic HCV Infection
Factors predictive for chronic HCV infection among exposed subjects who remained anti- 
HCV and HCV RNA positive at follow up, were examined by comparing HCV RNA positive 
subjects to HCV RNA negative subjects (Table 4.1 /).
On univariate analysis, HCV RNA positive subjects were more likely to have had histories of 
IDU. In those who had a history of IDU, HCV RNA positive subjects were likely to have 
injected more frequently - more than 3 times per week - and to have injected for longer periods 
of time than were those who were HCV RNA negative at follow-up.
Average lifetime consumption of alcohol - in average gms per week - was also a predictor for 
chronic HCV infection, although total duration of alcohol consumption was not. On 
multivariate analysis, frequency of injecting (adjusted OR 2.98, 95% Cl: 1.2 to 7.3, p=0.017) 
rem:uned significantly associated with chronicity and total average lifetime consumption of 
alcohol was of borderline significance (adjusted OR 1, 95% Cl: 1 to 1.01, p=0.055). Having a 
history of IDU, duration of injecting and frequency of injecting were too highly correlated and 
could not all be included in the model.
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4.6.3 Non Liver Related Morbidity
Fifty five percent (n=54) of the exposed group had at least one other medical condition 
requiring ongoing clinical care compared to 42% (n=77) of the unexposed group (RR 1.4, 95% 
Cl: 1.1 to 1.9, p=0.045). Exposed subjects, with active medical conditions, were significantly 
more likely than the unexposed group to have psychological or alcohol-related conditions and 
significandy less likely to suffer from gastrointestinal or genitourinary conditions (Table 4.12).
Table 4.12 Non liver related morbidity in exposed and unexposed cohort subjects who 
reported ongoing medical conditions
Anti-HCV 
positive 
(n =54)
Anti-HCV
negative
(n=77)
RR (95% Cl) p value
Cardiac 11% 21% 0.59 (0.26 to 1.3) 0.153
Respiratory 13% 6% 1.61 (0.9 to 2.9) 0.158
vYrthritis 17% 12% 1.32 (0.72 to 2.9) 0.427
Gastrointestinal 15% 36% 0.45 (0.22 to 0.92) 0.013
Malignant neoplasms 2% 5% 0.56 (0.96 to 3.30) 0.475
Neurological 6% 7% 0.92 (0.36 to 2.39) 0.866
Genitourinary 27% 46% 0.57 (0.32 to 0.99) 0.036
Psychological 23% 10% 1.79 (1.12 to 2.85) 0.033
jYlcohol related 4% 0% 2.92 (2.31 to 3.78) 0.007
Bodi exposed and unexposed subjects had an average of 2.5 surgical operations requiring a 
general anaethestic.
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4.6.4 Liver Related Morbidity
4.6.4.1 Unexposed (Anti-HCV Negative) Cohort
Six percent (n= ll) of the anti-HCV negative cohort had elevated ALT levels at follow-up 
(Table 4.13). Median ALT was 23u/l (NR 25-50 u/I) and median AST was 22u/l (NR 20-40 
u/1). Ail had a serum albumin concentration within the normal range and 97% had a bilirubin 
level within the normal range ( Table 4.13)
Three percent (n=2) had evidence of chronic liver disease (spider naevi, firm hepatomegally) 
on clinical examination - as documented by the examining doctor using the study clinical 
proforma. One had biopsy proven cirrhosis and evidence of portal hypertension (ascites, 
splenomegaly and caput medusa); alcohol was the likely aetiology. No cases of HCC were 
detected.
4.6.4.2 Exposed (Anti-HCV Positive) Cohort
In the anti-HCV positive cohort, LFTs at follow up were suggestive of relatively benign disease 
(Table 4.13). Forty one (42%) had elevated serum ALT levels (Figure 4.3). Subjects who were 
HCV RNA positive were significantly more likely to have elevated ALT levels (69%) than 
those who were HCV RNA negative (14%). Median ALT in those who were HCV RNA 
negative was 21 mmol/1 (IQ range 17 to 35) compared to 95 mmol/1 (IQ range 36 to 137) in 
HCV RNA positive subjects. Only one subject had a serum albumin level below the normal 
range, and the same individual had a bilirubin level greater than 40 umol/1. In total 7% of the 
exposed group had abnormal bilirubin levels (Table 4.14).
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Table 4.13 Median values of liver function tests at clinical follow up in the anti-HCV positive 
and anti-HCV negative cohorts
Anti-HCV positive 
(n=98)
Anti-HCV negative 
(n=185)
P
value
Median (IQ Range) Median (IQ Range)
Albumin (NR 30-50 g/1) 41 (38-44) 40 (37-43) 0.57
Alkaline phosphatase (NR 80-120u/l) 67 (64-69) 77 (72-81) 0.07
ALT (NR 25-50 u/1) 36 (20-78) 23 (17-32) <0.001
AST (NR 20-40 u/1) 28 (21-58) 22 (18-26) <0.001
GGT (NR 30-63 u/1) 32 (16-53) 22 (16-37) 0.016
Bilirubin (NR 10-20 umol/1) 10 (7-12) 10 (7-13) 0.17
Total protein (NR 65-80 u/1) 74 (71-77) 72 (70-75) 0.13
Table 4.14 Proportion of the anti-HCV positive and anti-HCV negative cohorts with 
abnormal albumin and bilirubin liver tests at clinical follow up
Anti-HCV positive 
(n=98)
Anti-HCV negative 
(n=185)
p value
Albumin (NR 30-50 g/I)
<30 g/1 1 (1%) 0 (0%) 0.236
31-35 g/1 11 (11%) 20 (11%)
36-40 g/1 34 (35%) 82 (44%)
>40 g/1 52 (53%) 83 (45%)
Bilirubin (NR 10-20 umol/1)
<20 u/1 90 (92%) 180 (97%) 0.77
21-25 u/1 3 (3%) 4 (2%)
36-40 u/1 4 (4%) 1 (0.5%)
>40 u/1 1 (0.4%) 0 (0%)
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In those who were HCV RNA positive at follow up, 14% (7/52) had evidence of chronic liver 
disease (firm hepatomegally) on clinical examination. Of these, 6% (3/52) had clinical 
manifestations of cirrhosis (i.e. portal hypertension), and 8% (4/52) had biopsy proven cirrhosis.
The HCV genotypes in those with evidence of chronic liver disease were -  la , lb , lb , lb , 3a, 3a, 
3a - and in those with cirrhosis; la , lb  and 3a.
In subjects who were HCV RNA negative, 5% (2/44) had progressed to cirrhotic liver disease 
during the period of follow up; one underwent liver biopsy in 1996 with histological findings 
more suggestive of alcohol as the aetiology rather than HCV. A further subject had liver 
transplant in 1989 for cirrhosis and is currently asymptomatic. All other RNA negative subjects 
were clinically well. No cases of HCC were detected in either group.
Serum Hyaluronate (non invasive marker of liver fibrosis)
In total, 14% (14/98) HCV seropositive subjects underwent liver biopsy in the five years 
preceding study follow up. In view of the lack of histological data on study subjects, serum 
hyaluronate (HA) was measured in the HCV seropositive group as a surrogate marker for 
hepatic fibrosis. Figure 4.5 demonstrates the correlation between serum ALT and serum HA 
levels.
Figure 4.5 Correlation between serum ALT and serum HA levels in exposed cohort subjects
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Altiiough serum HA principally measures hepatic fibrosis and serum ALT hepatic inflammation, 
in chronic HCV both processes are often evident and hence the noted correlation in our 
subjects. (Pearson’s correlation coefficient was significant at 0.627, p <0.0001).
Foity four percent of the exposed cohort had abnormal serum HA levels (>37|ig/l) suggestive 
of some degree of hepatitis fibrosis. Those who were HCV RNA positive were twice as likely as 
HCV RNA negative subjects to have elevated HA levels (64% vs 24%, RR 2.2, Cl: 1.3 to 3.7; 
p=0.003).
All with biopsy proven cirrhosis (n=5) had HA levels >170pg/l. Another study, which used the 
same methodology to measure HA levels, reported mean HA levels in those with biopsy proven 
cinhosis of 219|ig/l.237 In this study only 3 subjects (5%) had HA levels >200|ig/ml.
4.6.4.3 Rate Ratio Liver Morbidity at Follow Up
The rate of chronic hepatitis in the exposed group at follow up was 3.7 that of the unexposed 
grcup (Table 4. /5). Exposed subjects were 11.9 times more likely to have cirrhosis at follow up.
Table 4.15 Rate ratio of liver morbidity in exposed versus unexposed cohorts
Rate per l,0O0PY 
in anti-HCV 
positive cohort
Rate per 1,000 PY in 
anti-HCV negative 
cohort
Rate ratio 
(95% Cl)
p value
Chronic hepatitis 17.3 2.3 3.7 (2.7-4.8) P<0.0001
Cirrhosis 2.5 0.21 11.9 (5-19) p=0.04
HCC 0 0 - -
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4.7 Mortality Outcomes
4.7.1 All Cause Mortality
Tnirteen percent (20/152) of the HCV seropositive group and 7% (21/285) in the HCV 
seronegative were found to have died since the time of discharge from FIDH to the end of the 
fellow up period (31/12/98). The proportion of liver related mortality was 1.3% (2/150) in the 
exposed group and 0% in the unexposed.
The two liver related deaths in those anti-HCV positive were hepatic cirrhosis, in 1996 and 1998.
The main cause of death in the anti-HCV positive group was drug overdose (4%, 6/152) and 
suicide (2%, 3/152). Anti-HCV positive subjects were 4 times more likely to die from suicide or 
overdose than from HCV related liver disease (Table 4.16). None of those who committed 
suicide had been treated with interferon therapy.
Table 4.16 Underlying cause of death in anti-HCV positive and anti-HCV negative cohorts
Cause of death Anti-HCV positive 
(n=20)
Anti-HCV negative 
(n=21)
Liver cirrhosis 2 (10%) 0 (0%)
Cardiovascular disease 2 (10%) 4 (19%)
Malignant neoplasms 4 (20%) 5 (24%)
Opiate overdose 6 (30%) 1 (5%)
Suicide 3 (15%) 3 (14%)
HIV/AIDS 0 (0%) 1 (5%)
Motor vehicle accident 2 (10%) 1 (5%)
Other 1 (5%) 6 (30%)
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4.7.2 Standardised Mortality Rados
The all cause mortality rate was significantly higher in the exposed cohort than the general 
Australian population (SMR 333, 95% Cl: 121 to 912, p<0.001), but not in the unexposed group 
(SMR 116, 95% Cl: 93 to 143, p=0.479), Table 4.17. In the exposed cohort the mortality rate due 
to liver disease was 2.3 times higher than the general population, although this increased rate was 
not significant. The suicide rate in the exposed group was significantly greater at six times that of 
general population.
Deaths from liver disease or suicide in the unexposed group were no higher than that found in 
the general population.
Table 4.17 Standardised Mortality Ratio by ICD 9 classification categories in exposed (anti- 
HCV positive) and unexposed (anti-HCV negative) subjects
Anti-HCV positive cohort Anti-HCV negative cohort
Cause of Obs Exp SMR 95% Cl P Obs Exp SMR 95% Cl P
death* value value
All Cause 20 6 333 121 -912 <0.001 21 18 116 93-143 0.479
Liver 3 1.3 230 96 - 548 0.1658 0 1.2 - - -
Suicide 3 0.5 600 252 - 1428 0.0004 2 0.87 229 95-2189 0.227
•ICD-9
Obs = observed, Exp = expected number o f deaths based on Australian age and calendar-year specific rates
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4.7.3 Survival
OveraU survival for the period of follow up from admission to FIDH to death or the end of 
follow up period (31.12.98), is demonstrated in Figure 4.6.
There was no significant difference in the proportion surviving in each group (Log-rank test for 
equality of survivor functions: chi2 = 3.64, p= 0.0564)
Figure 4.6 Kaplan-Meier survival estimates, by exposure
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4.8 Quality of Life Outcomes
4.8.1 Quality of Life
Subjects who were anti-HCV positive had a significantly poorer quality of life scores in six out 
of the eight scales (Table 4.18), indicating that the exposed cohort subjects had a subjective 
perception of very poor physical and mental health. The only areas with no significant difference 
were in physical functioning and bodily pain.
Table 4.18 Mean Short Form 36 scores in anti-HCV positive subjects compared to anti-HCV
negative subjects
Anti-HCV Anti-HCV Mean Difference p value
positive mean negative mean (95% Cl)
(SE) (SE)
Physical functioning 75 (2.9) 80 (1.6) -5.3 (-11.9 to 1.4) 0.119
Role limitation physical 58 (4.9) 74 (2.9) -16.3 (-27.5 to -5.1) 0.004
Bodily pain 63 (2.7) 69 (1.6) -6.1 (12.4 to 0.14) 0.056
General health 50 (3.0) 66 (1.7) -15.8 (-22.5 to -8.9) 0.000
Vitality 49 (2.6) 60 (1.7) -10.9 (-16.9 to -4.8) 0.001
Social functioning 66 (3.2) 81 (1.8) -15.0 (-22.3 to -7.8) 0.000
Role limitation emotional 59 (5.0) 75 (2.7) -15.3 (26.5 to -4.0) 0.008
Mental health 63 (2.3) 74 (1.4) -10.6 (-15.9 to -5.8) 0.000
4.8.2 Impact of a Diagnosis of Hepatitis C on Quality o f Life
To measure the impact of a diagnosis of hepatitis C on quality of life we compared the SF-36 
see res of chronically HCV infected subjects who were aware of their serostatus at the time of 
completion of the SF-36 questionnaire, to those who were unaware.
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Subjects were excluded from this analysis if found to be currendy anti-HCV or HCV RNA by 
PCR negative, have cirrhosis or clinically detectable liver disease, if symptomatic at the time of 
their recent anti-HCV testing or with medical conditions other than HCV which could affect 
qujdity of life.
Of the 34 chronically HCV infected subjects (anti-HCV positive and HCV RNA by PCR 
positive at follow up) included in the QOL analysis, 15 (44%) already knew of their HCV status 
prior to follow-up contact. Testing for anti-HCV had been undertaken for a variety of reasons 
including; patient request due to a previous history of IDU or an ex-injecting partner being 
diagnosed with HCV (5), GP recommendation due to a history of IDU (4), screening prior to 
blood donation (2), routine health screen (2) or during participation in other research studies (2). 
None had been tested because they were symptomatic. The mean length of time since diagnosis 
was 2 years (SD 1.1 years). The remaining 19 were unaware of their HCV serostatus when they 
were recruited and completed the SF-36 scale.
Stratified analysis of SF-36 scores found that those aware of their positive HCV serostatus had a 
significant reduction in QOL scores in seven out of eight scales compared to population norms 
(Table 4.19). These individuals had a subjective perception of extremely poor physical and mental 
health leading to limitation of daily activities, bodily pain, poor social functioning and emotional 
problems. In contrast, the group who were unaware of their positive HCV status had 
significantly lower QOL scores in only three scales (general health, vitality and mental health).
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Table 4.19 Mean Short Form 36 scores by awareness of sero-status in anti-HCV positive and PCR 
positive individuals, compared to population norms
Population anti-HCV &HCV PCR positive study subjects
Norms
(SE) Aware of sero-status Unaware of sero-status
n=15 (SD) n=19 (SD)
Physical functioning 86 (0.5) 82 (17) 91 (14)
Role limitation physical 83 (0.8) 58 (45)* 75 (42)
Bodily pain 78 (0.6) 67 (26)** 82 (23)
General health 73 (0.5) 43 (27)*** 64 (25)***
Vitality 66 (0.5) 49 (20)*** 60 (21)***
Social functioning 86 (0.5) 65 (18)*** 83 (25)
Role limitation emotional 85 (0.8) 64 (43)* 84 (30)
Mental health 74 (0.4) 66 (11)*** 71 (19)**
p < 0.05 compared to population norms 
p < 0.01 compared to population norms 
p < 0.001 compared to population norms
Those aware of their positive HCV serostatus did not differ from those who were unaware 
sodo-demographically, on risk history, biochemically or virologically (Table 4.20).
The only difference was that those who were aware of their diagnosis were less likely to 
currendy drink, probably reflecting medical advice given at the time of diagnoses. None had 
been treated or were being treated with standard therapies (interferon +/- ribivirin) or 
naturopathic remedies. Both groups had comparable histories of previous IDU and no subjects 
had injected within the previous 24 months. No individuals had a history of depression or any 
other current illness likely to affect QOL. In addition, there was no link between knowledge of 
HCV status (and reduced QOL) and objective measures of ill health such as abnormalities on 
physical examination or elevated ALT. The differences in QOL scores remained after 
adjustment for age, sex, marital status and serum ALT levels (Figure 4.7).
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Table 4.20 Sociodemographic, clinical and serological comparison at the time of QOL testing of those 
aware of positive HCV serostatus and those unaware
Anti-HCV and PCR positive subjects 
Aware of sero-status Unaware of sero-status 
(n=15) (n=19)
p value
Mean age in years (SD) 44(2) 42(2) 0.16
Malt (%) 10 (67%) 10 (53%) 0.32
Bom in Australia (%) 10 (67%) 16 (84%) 0.37
Never married (%) 2 (13%) 3 (16%) 0.86
Manied/defacto (%) 9 (60%) 9 (47%)
Divorced (%) 3 (20%) 6(32%)
Other (%) 1 (7%) 1 (5%)
History of IDU (%) 15(100%) 19 (100%) 0.07
Mean no of years IDU (SD) 13 (10) 8(10)
Injected in past 24 mths (%) 0 (0%) 0 (0%)
Mean yrs dur’n alcohol use (SD) 18(8) 19(9) 0.75
Mean number of gms/day (SD) 31 (32) 32 (33) 0.89
Reported binge episodes (%) 10 (77%) 11 (69%) 0.47
HBcAb positive (%) 10 (67%) 11 (58%) 0.18
HBsAg positive (%) 0 (0%) 0 (0%)
Mean ALT (SD) [NR 25-50 u/1] 92 (86) 98 (86) 0.83
Mean AST (SD) [NR 20-40 u/I] 59(37) 57(47) 0.92
Mean GGT (SD) [NR 30-63 u/I] 74 (144) 62 (75) 0.75
Genotype 1/la/lb 6 (40%) 9 (47%) 0.67
Genotype 2b 2 (13%) 1 (5%)
Genotype 3a 7 (47%) 9 (47%)
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Figure 4.7 Mean difference in SF-36 quality of life scores between population norms and 
anti-HCV and PCR positive individuals aware of serostatus (n=15) and unaware 
of serostatus (n=19), after adjusting for age, sex, marital status and ALT levels.
•  Positive anti-HCV status known
O Positive anti-HCV status unknown
Physical functioning 
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Bodily pain 
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CHAPTER 5: DISCUSSION
Infection with the Hepatitis C vims (HCV) is widespread and continues to spread at a rapid rate 
in vulnerable sections of the population, such as IDUs.48 59 60 An estimated 150,000 people are 
chionically infected with HCV in Australia as a result of IDU, with a further 11,000 becoming 
infected each year.48 Similar scenarios are evident in the UK, the USA and other industrialised 
nations.30 57 247 248 As acute HCV infection is generally benign (with estimates that less than 15% 
are icteric),249 the major associated medical and public health significance of infection is the 
development of chronic liver disease.
For policy makers, people with chronic HCV infection, clinicians and others a fundamental 
question has been how many of those infected will progress to adverse outcomes and over what 
time period. Answering this question is difficult as knowledge of the natural history of 
community acquired HCV infection remains limited, primarily due to the methodological 
difficulties associated with conducting these studies. Such difficulties include the problems of 
accurately identifying those with incident infection, the long latent period before development of 
liver-related disease and difficulties in following up the largest affected group, IDUs, over long 
periods of time.
In the past five years there has been much progress in our understanding of the natural history 
of HCV. However, the estimated risk of progression to serious sequelae of HCV infection 
differs depending upon the populations studied, the methods used and the period of follow up. 
Transfusion related studies report rates of progression to cirrhosis of over 20% at 20 years.249 
Liver clinic series have also estimated rates of progression to cirrhosis similar or greater to those 
of transfusion related studies,154 however it is likely such series suffer from considerable referral
5.1 Implications of the Study
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bias. There have been very few population-based studies with any significant follow up. Of 
these, two are based on point source outbreaks from contaminated anti-D immunoglobulin.74 75
The picture that is emerging from population based studies such as ours contrasts considerably 
wiih that reported in liver clinic patients and transfusion recipients, with few subjects (2-8%) 
progressing to advanced liver disease at 20 years after infection. It is likely that the Irish and 
German anti-D studies are at the opposite end of the spectrum from transfusion acquired 
disease in terms of progression to cirrhosis, with our study identifying rates somewhere in- 
between. It may be that the findings of studies such as ours may be of greater significance for 
the future, with clarification of the natural history of relatively rare transfusion or anti-D related 
HCV infections becoming less clinically important.
In this study we traced and followed up members of a cohort who on retrospective testing, were 
positive for HCV antibody at the time they were admitted to FIDH with hepatitis during the 
ye i^rs 1971 to 1975. This study has overcome many of the methodological problems outlined 
above, and is unique in its length of follow up and freedom from confounding bias due to 
treatment, as 98% of subjects studied were interferon-naive and the 2% treated, had interferon 
therapy for less than 12 weeks in total.
Our results are among the first to challenge the accepted litany of 20 % progression to cirrhosis 
at 20 years in those infected with HCV. It is also among the first to challenge the accepted 
chronic HCV carriage rate (quoted at 80%250) in those infected with community acquired HCV, 
as we found that just over half of our cohort had chronic HCV infection (by anti-HCV and PCR 
results). Our study is also unique in terms of follow up length, having already accrued a follow 
up period of 25 years, which is greater than any other published study, except for one that had 
only 17 subjects.171
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Excess mortality was evident in the anti-HCV positive cohort, but was predominantly due to 
overdose or suicide rather than liver related disease and there was no significant difference in 
survival rates between the anti-HCV positive and anti-HCV negative cohorts.
Anti-HCV positive individuals who completed follow up, were found to be at increased risk of 
live r related pathology, though few (6% overall) had progressed to overt cirrhosis in the 25 years 
since admission and no cases of HCC were identified.
Our findings suggest that the natural history of community acquired HCV may be more benign 
than previously thought.
5.2 Power. Bias and Confounding
5.2.1 Power
Recruiting sufficient numbers was difficult as the cohort studied consisted predominantly of 
people with histories of IDU from at least 25 years ago. Nevertheless, a cohort of this sixe 
enabled us to provide useful estimates of disease progression and factors impacting on 
progression to chronicity, though it may not have been large enough to explore detailed issues 
such as the influence of specific host (e.g. diet) or viral (e.g. genotype) factors on the 
development of liver disease. In addition the low numbers of individuals developing liver 
disease in our cohort made it difficult to determine cofactors influencing disease progression.
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5.2.2 Selection Bias
The anti-HCV positive cohort consisted of injecting drug users admitted with acute hepatitis -  
the majority with acute HAV or HBV - to FIDH in the early 1970s. They are likely to be 
representative of community acquired HCV infection in Melbourne in the 1970s, as during this 
time acute hepatitis was common among IDUs and all persons with a clinical diagnosis of 
heoatitis in the Melbourne Metropolitan area were admitted to FIDH. In line with current 
concepts of community acquired hepatitis C, more than 80% of the HCV seropositive 
individuals appear to have sub-clinical HCV infection rather than acute symptomatic HCV on 
admission, being already anti-HCV positive at the time they were hospitalised for acute HAV or 
HBV. Indeed only a small proportion of the 17% of the anti-HCV positive cohort with no 
ev:dence of other acute viral hepatitis markers at the time of admission were likely to have had 
acute HCV. This is due to the fact that clinically evident acute HCV is uncommon in IDUs and 
that the appearance of anti-HCV in serum often occurs after symptom onset251
Th e possibility of introducing bias by selecting participants on the basis of co-infection with 
other hepatitis viruses is unknown, but unlikely to be significant as acute HAV is a self-limiting 
infection, and none of the anti-HCV positive group with acute HBV on admission became 
chronic carriers. However, the impact of an acute episode of non-C hepatitis or occult HBV 
infection on long-term outcomes in subjects with chronic HCV infection is unknown and the 
selective nature of our cohort in this respect should be noted.
IDU was the most probable source of HCV infection in the majority of subjects and as the mean 
time of IDU prior to admission to FIDH was 1.5 years, it is very likely that acquisition of HCV 
infection occurred during this time.
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The recruitment rate was good and as such we believe that selection bias is unlikely to be 
significant in this study. Serological markers, basic socio-demographic data, and risk behaviours 
were all similar between those recruited and those who did not participate. We were less likely to 
trace those with a history of IDU and this is doubtless due to the intentional invisibility of this 
section of the community. However as the majority of the traced anti-HCV positive cohort were 
injecting drug users, it is likely that the cohort is representative.
In this cohort, an internal comparison group was used i.e. those admitted to FIDH with clinical 
hepatitis who did not test anti-HCV positive on stored sera. They were realistically the only 
avjilable control group due to the fact that they had sera stored from the same time period as 
the cases. Both groups had identical follow up and assessment for outcomes. The groups were 
comparable except that the unexposed control group was slightly older and less likely to have a 
history of injecting drug use than the exposed group. It is unlikely that a history of IDU 
increases the risk of severe liver disease except by its associations with HBV and increased 
alcohol use, both if which were controlled for in the analysis. The increased age of the control 
group was significant, but after being controlled for in the analysis it was considered unlikely to 
affect study outcomes, although advanced age is associated with a higher incidence of liver 
disease, in particular HCC.252
5.2.3 Measurement Bias
Significant misclassification of hepatitis status appears unlikely as there was moderate to good 
agreement on comparison of original results for hepatitis A and B with results of current testing. 
In addition, a more stringent cut off was used to classify HCV antibody status and this increased 
specificity and reduced misclassification bias.234
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The use of clinical examination and LFTs alone, without histological diagnosis, to assess the 
degree of liver injury is fraught with difficulties. Standardised clinical assessment forms were 
used to try and limit variation in clinical observations, although the worth of clinical examination 
p e r  se in assessing liver status is debatable. To compensate for this, clinical examination was 
supplemented by more reliable means of assessing outcomes including laboratory indices, the 
use of ultrasound and where possible examination of liver histology.
It is accepted that elevated ALT does not directly correlate with the degree of hepatocellular 
injury, though in one study peak ALT levels and biopsy scores (Knodell and Sheffield) were 
strongly correlated.253 Several studies have demonstrated that chronic liver disease is also likely 
in those who have antibodies to HCV, but normal ALT concentrations and no biochemical or 
radiological evidence of liver disease.158 254 Liver biopsy is well established as the gold standard 
for staging HCV related liver disease in terms of severity of fibrosis and cirrhosis.
Unfortunately, a minority of participants underwent liver biopsy due to the nature of the study, 
the cohort involved, and the fact that responsibility for the ongoing care of many subjects was 
with the treating physicians and not the investigators. This may have led to an underestimation 
of the percentage of subjects with cirrhosis. To reduce this possibility, we measured serum 
hyaluronate levels, which have been shown to correlate well with fibrosis in numerous studies 
and which are relatively sensitive and specific for detecting cirrhosis in hyaluronate levels highly 
predictive of cirrhosis, and in all of these, the diagnosis of cirrhosis was already established.
In other studies, laboratory indices such as serum bilirubin, albumin and platelets have been 
demonstrated to indicate the severity of underlying liver disease and the likelihood of 
progression to liver related complications.132 186 In one study, patients with a serum albumin 
concentration <30g/l had an 85% chance of progression to severe liver related complications P ‘ ^  
after 5 years.186 In our study only one individual had a serum albumin less than 30g/l and they
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had already been diagnosed with cirrhosis. The same individual was the only study subject to 
have a bilirubin level >40mol/l, which is associated with a 25% chance of progression to severe 
liver disease.186
Thus, while an under-reporting bias cannot be excluded, the effect is likely to be relatively small.
5.2.4 Confounders
Information was collected on potential cofounders of the effect of HCV infection on outcomes, 
and study risk estimates were adjusted to take account of known confounders. The most 
important confounder is lifetime consumption of alcohol. Underestimation of alcohol 
consumption may have led us to over estimate the impact of HCV on outcomes. It is also 
possible that unknown confounding factors were not taken into account.
Lifetime alcohol consumption: Alcohol is one of the major causes of severe liver disease 
including HCC.257 258 There is strong evidence that HCV and alcohol act synergistically to 
increase the risk of liver disease.185 192 193 It is possible in this study that subjects under reported 
alcohol consumption because of social stigma. However in this cohort the candour with which 
they discussed an illicit activity such as IDU makes it unlikely that they were less that truthful 
about their alcohol habits. It is more likely that some subjects simply could not remember details 
of consumption during certain periods of their lives and may have under or overestimated 
alcohol habits.
Co -infections: HBV is independently associated with severe liver disease and also acts 
synergistically with HCV, in particular in the development of HCC.200 259 We measured HBcAb 
anc HBsAg in both the exposed and unexposed cohorts to assess previous exposure and current
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carriage of HBV. None of the exposed cohort were HBsAg positive at follow up but we did not 
measure HBV DNA in HBcAb positive subjects. We may therefore not have detected subjects 
witn so called ‘occult’ HBV infection, although the clinical significance of this remains unclear.
HIV is not associated with chronic liver disease, although it does act synergistically with HCV to 
increase progression to severe liver disease.68 We did not measure HIV status in study subjects 
due to ethical constraints, unless it was otherwise indicated. It is unlikely that any would have 
tested HIV positive as the majority of subjects had no risk factors for acquisition of HIV having 
ceased IDU over a decade ago, and in any case the risk of acquiring HFV through injecting drug 
use in Australia is very low.27
Smoking: Smoking is implicated as a risk factor for HCC.260 263 There is evidence that it may 
also act as a cofactor with HCV to increase the severity of HAI scores and also in the 
development of HCC.264 Information on lifetime smoking habits were obtained from study 
subjects.
Sociodemographics: Age and gender are independently associated with liver disease, in 
particular HCC.252 259 265 266 There is a higher incidence of HCC in males than in females with a 
male: female ratio between 2 and 4. Most studies hypothesise that differences in hormone status 
between males and females plays a significant role, but the exact mechanism remains poorly 
understood. The incidence rate of HCC also increases with age.
Other: Information was collected on patterns of oral contraceptive and anabolic steroid use as 
botii are associated with an increased risk of HCC.252 Information was also collected on other 
co-morbidities that may impact on the development of liver disease, including iron overload 
conditions.
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5.3 Seroprevalence of HCV in Melbourne in the Early 1970s
Measurement of anti-HCV in the stored sera confirms that anti-HCV was present among adults 
admitted with acute hepatitis to FIDH in Victoria in the early 1970s and also that prevalence 
increased markedly during the period between 1971 and 1975. Most cases were in young men 
who had a history of IDU.
The original admission of the majority of individuals with HCV appears to have been 
precipitated by subsequent infection with hepatitis A or B. The actual proportion is unclear, but 
is likely to be significant, as only 16% of HCV seropositive individuals had no evidence of other 
acute hepatitis markers. This implies that individuals with subclinical acute HCV infection were 
admitted and therefore included in the study. The significant association between the presence 
of HCV antibody and documented contact with a hepatitis case probably results from a spurious 
association with the HAV or HBV infection that precipitated admission. This also reflects that 
those infected with HCV were likely to have risk behaviours that exposed them to other 
hepatitis viruses, in particular HBV.
The presence of tattoos and a history' of blood transfusion were not identified as significant risk 
factors for HCV seropositivity probably reflecting the low prevalence of HCV in the general 
population at this time.
The significant increase in the prevalence of HCV over the five year period studied suggests that 
infection became firmly established within the Australian community, particularly the IDU 
population, as early as the mid 1970s. One potential source of infection could have been 
American servicemen who used Australia regularly as a ‘rest and relaxation’ base during the 
Vietnam War. It is known that over 20% of the troops were IDU, 267 and studies have 
documented the presence of HCV in American Vietnam 268 and Korean 171 war veterans. It is
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likely that serviceman gained access to local Australian injecting networks and unsafe injecting 
practices would have ensured rapid spread of the virus once introduced.48 Another possible 
source of infection was the migration of a population infected as a result of unsafe vaccination 
practices in Europe after the Second World War.
It is evident that the Australian IDU population expanded dramatically in the late 1970s and 
ear y 1980s and it is likely that the majority of the 140,000 Australians currendy infected with 
HCV became infected in the last two decades.48 This is supported by our results, which 
documents a two-fold increase in the recording of IDU among all admissions with viral hepatitis 
for the period between 1971 and 1975.
5.4 Tracing and Recruiting Subjects with a History of IDU
Thi s study is unique in examining the feasibility of establishing a cohort of individuals, including 
a high proportion of IDUs, 25 years after hospitalisation with hepatitis. Completeness of case 
finding and recruitment was essential to avoid inaccuracy in measurement of outcomes of 
infection with hepatitis C.
Studv funds were limited and two-thirds of the final cohort were located through relatively 
inexpensive means with important outcomes identified. We found that IDUs were less likely to 
be traced than non-IDUs possibly due to the often-intentional invisibility of this section of 
society. Other studies have found IDUs undertake frequent name changes and use aliases, 
nicknames or street names to avoid detection.269 This practice severely limits the ability to trace 
participants especially after almost three decades have elapsed.
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Unlimited study funds and time may have allowed us to detect further subjects, principally 
through systems tracking.270 It is unlikely however that in Australia we could have easily gained 
access to social security, vehicle registration or penal records, as our initial inquiries were met 
with firm refusals by the organisations concerned. In addition, the ethical issues involved in 
accessing this non-health information are not insignificant.
We found that accurate ascertainment of birth date and full name - including middle name - 
from original case records was essential for tracing purposes. The practice of destroying inactive 
patient files, which has become common practice in Public Hospitals, may adversely affect 
future retrospective study initiatives. In addition, if false details were given at the time of 
admission or inaccurately transcribed there is little hope of tracing the subject.
Coirect identification using the electoral roll and CD-ROM telephone directory was the norm, 
with less than 5% of attempts proving to be mismatches. This was a relatively inexpensive and 
productive means of locating study subjects. Telephone directories for many countries are also 
available free of charge on the World Wide Web,271 although the ability to search on different 
fields is less well developed than on CD-ROM. We had extremely few complaints from subjects 
contacted, principally due to the discreet and sensitive manner by which the initial contact was 
made with the subject.
Advertisements in major daily newspapers were an expensive and unproductive exercise. Only 
1% of study subjects were located through this method, and numerous calls resulted from 
individuals with wide ranging queries unrelated to the study. Approaches to doctors recorded in 
the FIDH medical records met with little success, mostly due to the now common practice of 
destroying inactive patient files. Next of kin tracing became crucial to finding women, who had 
possibly married and changed their surname.270 Word of mouth played a very minor role in the 
search, but made many recruitment phone calls easier.
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Heilih Insurance Commission records were used as the last resort to fmd those not located by 
other means. Computerisation of Health Insurance records occurred in 1982 and it was unclear 
at what point from that date the contact address referred to, as the Commission would release 
only the subjects address and not any details of date of last contact with services. The speed with 
wh.ch the Commission searched their data-base and returned contact details to the study centre, 
in addition to the small cost required, makes this a very cost effective method of tracing if  the 
aims of the study are judged justifiable by the Health Insurance Commission.
Participation rate was high in those traced. This did not differ between the exposed and 
unexposed groups. It perhaps demonstrates the willingness of individuals to participate in a 
study that may not directly benefit them, although the opportunity to have their current health 
status assessed was appealing to many. The use of experienced study personal to make the initial 
contact is essential,269 272 and extra care and discretion had to be employed due to the sensitive 
nature of the study.
The study questionnaires determined detailed and personal information including a history of 
IDU. For many of these subjects such histories were unknown to their families and the 
wilingness of subjects to trust the study team to maintain the confidentiality of such 
information would appear to be due to the positive relationship developed with the staff 
member responsible for the initial contact and recruitment. Once more this factor has been 
identified as crucial for study success with ‘hard to reach’ populations.269 272 273
We demonstrated that it is possible to trace a population - including a large proportion of 
subjects with histories of IDU - 25 years after last contact. Methods of tracing used do not have 
to be overly expensive or sophisticated although the use of a skilled and experienced tracer is 
essential.
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5.5 Outcomes of Infection with HCV 25 Years after Initial Infection
5.5.1 Quality of Life
Our study results indicate that QOL is markedly reduced in subjects with hepatitis C compared 
to population controls. This finding has been documented in other studies that also report 
disabling fatigue and a reduced sense of well-being in many patients with chronic HCV 
infection.220 222 274 275 These studies could not however determine the impact of HCV diagnosis 
p er  se on QOL as all patients were aware of their diagnosis at the time of completion of the QOL 
scales.276
We wished to explore the hypothesis that subjective health perceptions are influenced by 
diagnosis with HCV. To assess the impact of a diagnosis of HCV on QOL in our anti-HCV 
positive cohort we compared QOL scores between those aware of their serostatus at the time 
QOL scores were measured, and those that were not aware.
Individuals with chronic HCV who were aware of their serostatus prior to interview had a 
significantly worse subjective QOL compared to population controls than those who were not 
aware of their serostatus. Both groups had been infected with HCV for an average of 25 years.
The reduction in QOL scales in those aware of serostatus was almost universal and affected 
variables measuring both emotional and physical health, and also those measuring the impact of 
health on activities of daily living. Those unaware of their diagnosis scored poorly in only three 
modalities; in addition they did not perceive that their emotional or physical health impacted in 
any way on daily activities.
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The fact that the unaware group did differ from population norms in the areas of vitality and 
gereral health suggests that the commonly reported symptoms of fatigue and tiredness in those 
with HCV may be secondary to a physiological, but as yet unclear, mechanism rather than any 
psychological process. A recent study identified elevations in basal ganglia and white matter 
choline/creatine ratios in patients with histologically mild HCV, compared with healthy 
volunteers and patients with HBV.225 The clinical significance of this is far from clear however.
In [his study it is not clear how much of the reduction in QOL in either group is attributable to 
chronic HCV and how much it may be associated with psychological disturbance, previously 
documented in IDUs,227277 that can adversely affect QOL. It was not possible in this study to 
independendy assess the impact of chronic HCV (without a history of IDU) on QOL, as all 
subjects were ex IDUs. Any impact however would have affected both groups equally and 
cannot be held responsible for the noted differences in QOL between the groups.
What is clear from this study is that subjects who have been diagnosed with HCV have a global 
and significant reduction in QOL compared to individuals with chronic HCV who have not yet 
been diagnosed. There is a growing body of literature indicating the impact of HCV infection 
on QOL. These results provide evidence of a possible major aetiology reduced QOL, namely 
the potentially adverse consequences of the knowledge of a diagnosis of HCV, unrelated to 
objective measures of pathogenicity.
Th ough unexamined confounding factors may remain as explanations for this observation it is 
unlikely that any factors other than the diagnosis of HCV could have led to this observed 
difference. Those aware of their positive serostatus did not differ sociodemographically, 
clinically, virologically or serologically from those who were unaware. All had asymptomatic 
liver disease and none had chosen to be treated with interferon. There was no link between 
QOL scores and objective measures of ill health and in all cases HCV diagnosis had been made
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inc: dentally and not because of the presence of symptoms. All were ex IDUs though none had 
injected in the previous 24 months.
A diagnosis of HCV raises significant concerns about current and future health status, 
compounded by the current inability to confidendy assess prognosis, as the natural history of 
community-acquired HCV is poorly defined. The ominous prediction that 60% of those 
infected will develop chronic liver disease with 20% progressing over 15 to 30 years to cirrhosis 
and a subsequent 2-7% developing HCC is derived mainly from studies relating to transfiision- 
acqiured disease, and may not be true in those with community acquired disease. It may 
therefore not be surprising that a diagnosis of a chronic illness with an uncertain prognosis will 
affect individuals QOL.
In addidon many of our subjects were infected with HCV as young adults through injecting drug 
use. The majority ceased injecting drugs some time previously, and in many cases this part of 
their lives remained unknown to family and others till HCV was diagnosed. Discrimination or 
rec rimination from family, friends, employers and others would also affect psychological and 
emotional well-being which is recognised to be a major determinant of overall QOL.
Therefore, although infection with HCV and/or a history of IDU may be associated with 
impaired QOL, the globally reduced QOL in the diagnosed group in our study may also be an 
effect o f ‘labelling,’ by which diagnosis of chronic disease p er  se affects subjective psychological 
well being.278Appropriate and sensitive management of the process of imparting a diagnosis of 
HCV may help to reduce the negative effects of diagnosis.
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5.5.2 Morbidity and Mortality
Only about half the cohort (54%) had evidence of chronic HCV infection based on positive 
anti-HCV and HCV RNA results. Other studies have reported rates of chronic infection with 
HCV (defined as persistence of HCV RNA for greater than six months) of over 80%.249 250 Low 
chronic carrier rates of HCV have been reported in children,183 and subjects infected as young 
women75 raising the possibility that the patients age at the time of infection is a factor in 
determining whether chronic infection occurs. Our study subjects had a mean age of less than 19 
years at infection and may be a contributing factor to the low chronic HCV carriage rates 
observed. It may also indicate that chronic HCV carriage in community acquired HCV may be 
less frequent than previously thought.
Factors associated with progression to chronic HCV infection in our subjects were being an 
IDU, increased frequency of IDU, increased total duration of IDU and higher average weekly 
alcohol intake than those who did not progress. In those with increased frequency of injecting 
anc a longer overall duration of injecting, repeated exposures to small doses of the virus or 
infection with multiple HCV genotypes may have promoted progression to chronicity. Our 
results, in line with numerous other studies,153 164 185 192 193 279 also suggest that excess alcohol 
inti ike promotes chronicity of infection, possibly through alcohol's effect on viral replication, or 
by .ts effect on the immune system.
We found that 31% of those with chronic HCV infection had normal serum ALT levels and no 
biochemical or clinical evidence of chronic liver disease. Although individuals with chronic 
HCV infection and initially normal ALT levels can develop abnormal LFTs, the overall 
progression rate among this group appears to be low. Our results support the suggestions that 
the vast majority of HCV infected people with normal LFTs appear at low risk of long-term 
complications of chronic HCV infection.121 123 280 281
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Only 8% of the chronically HCV infected group (and 6% of the overall HCV seropositive 
group) had progressed to clinically apparent cirrhosis after a mean follow up time of 26 years 
and no cases of HCC were detected.
There was no difference in survival between the exposed and unexposed cohorts. However, 
excess mortality was evident in the HCV seropositive group who were four times more likely to 
die from drug overdose or suicide than from HCV-related disease. Increased mortality in IDUs 
from suicide and overdose have been previously documented,282 283 as has the presence of 
psychiatric morbidity which in many cases is unidentified and untreated.227 283 The risk of
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overdose is ever present for IDUs, who by the illegal nature of their activity are forced to 
operate without the support of medical or counselling facilities. Our results highlight the fact 
that efforts to reduce mortality in those at risk of HCV infection should not neglect factors that 
appear to have overall a greater impact on survival than HCV.
The estimated risk of progression to serious sequelae of HCV infection differs depending on the 
populations studied and the methods used. Transfusion related studies report rates of 
progression to cirrhosis of over 20% at 20 years. The apparently more rapid progression among 
people with HCV infection acquired through transfusion of contaminated blood products 
compared to our subjects, may be due to the higher initial HCV inoculum relative to other modes 
of transmission such as IDU as well as the generally advanced age of transfusion recipients. Liver 
clinic series have also estimated rates of progression to cirrhosis similar or greater to those of 
transfusion related studies, however it is likely such series suffer from considerable referral bias. 
There have been relatively few population-based studies such as ours on the natural history of 
chronic HCV infection.74 75 284 Nonetheless the picture which is emerging from such studies 
contrasts considerably from that of liver clinic series, with few subjects progressing to advanced 
liver disease.
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Although the milder clinical picture in our study group may be due in part to the lack of 
histological diagnosis of liver disease or differential follow up, it appears to indicate that those 
with community acquired HCV follow a more benign clinical path than previously thought and 
tha>: the majority of HCV infected people may not progress to advanced liver disease.
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5.6 Summary of Study Findings
Our study makes a significant contribution to knowledge in this area.
1. This manner in which this study was designed has overcome many of the methodological 
problems encountered in studying the natural history of HCV, and is unique in its length of 
follow up and freedom from confounding bias due to treatment.
2. There was no difference in survival between the anti-HCV positive and anti-HCV negative 
cohorts although excess mortality was evident in the HCV seropositive group who were 
four times more likely to die from drug overdose or suicide than from HCV-related disease 
in the 25 years from infection.
3. Only about half the cohort (54%) had evidence of chronic HCV infection based on positive 
anti-HCV and HCV RNA results. Other studies have reported rates of chronic infection 
with HCV (defined as persistence of HCV RNA for greater than six months) of over 80%.
4. Factors associated with progression to chronic HCV infection in our subjects were being an 
IDU, higher frequency of IDU, longer total duration of IDU and higher average weekly 
alcohol intake than those who did not develop chronic infection.
5. We found that one third of those with chronic HCV infection had no biochemical or 
clinical evidence of chronic liver disease. Our results support the suggestions that the 
vast majority of HCV infected people with normal LFTs appear at low risk of long-term 
complications of chronic HCV infection.
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6. Only 8% o f the chronically HCV infected group (and 6% o f the overall HCV 
seropositive group) had progressed to clinically apparent cirrhosis after a mean follow up 
time of 25 years and no cases of HCC were detected. Our study provides the most 
significant evidence to date that community acquired HCV does follow a more benign 
path than previously predicted.
7. Quality of life measures were significandy worse for HCV seropositive individuals aware of 
their serostatus, compared to those unaware. We were able to investigate the impact of 
diagnosis of HCV p e r s e  on quality of life, and found that reduced quality of life in those 
diagnosed with HCV may be unrelated to any pathogenic effect of the virus and may 
partially be an effect of 'labelling'. The impact of the diagnostic process alone on quality of 
life in individuals with HCV requires further evaluation.
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